8 Genetic Counselors in Biotech: Bringing the Clinic to Industry

11 1,000 Members Packs a Policy Punch

12 Meet Biocom’s 2017 Life Science LifeLines Catalyst Award Winners For the California Life Science Community

VOLUME 26, ISSUE 3 Fall 2017 ONE TEAM. ONE FOCUS. www.sdlifesciences.com

RECENT TRANSACTIONS

LILLY TAKEDA METACRINE 300,000 SF Tenant Representation 164,000 SF Tenant Representation 20,000 SF Tenant Representation

BIOLABS ARCTURUS THERAPEUTICS HERON THERAPEUTICS 16,000 SF Tenant Representation 10,000 SF Tenant Representation 28,200 SF Tenant Representation

CLIENT TESTIMONIALS

“They helped Takeda to “C&W Life Sciences was a great “They are the “go to” real understand the market, carefully partner for our company. Their estate team for the life science consider all viable alternatives, specialization in life sciences real industry. I trust them and highly and arrive at a custom solution estate enabled us to get great recommend them.” with exceptional economic and space with flexible terms for our Magda Marquet other lease terms.” corporate headquarters.” Ph.D. Co-Chairman & Founder David Weitz Joe Payne Althea Technologies Head of Takeda California and President & CEO Global Research Externalization Arcturus

BRENT JACOBS [email protected] LEADING TENANT CA License No. 791657 GREG BISCONTI [email protected] ADVISORS FOR THE CA License No. 1167920

TED JACOBS LIFE SCIENCES [email protected] CA License No. 1855220

INDUSTRY (858) 452-6500 ONE TEAM. ONE FOCUS. www.sdlifesciences.com

RECENT TRANSACTIONS WELCOME IN THIS ISSUE By Joe Panetta, President and CEO, Biocom 4 Cover Story: Strength in Numbers 8 Guest: Genetic Counselors in Biotech: Bringing the Clinic to Industry 11 Public Policy: 1,000 Members Packs a Policy Punch Greetings and welcome to our fall 2017 issue of LifeLines, whose theme is the 12 Featured Story: Meet the 2017 Life Science strength of our association as we reach the milestone of 1,000 members across the Catalyst Award Winners state of California. Much of this growth is attributable to retaining our valued members LILLY TAKEDA METACRINE 19 Guest: Understanding New Therapies and greatly increasing our membership, especially through state-wide expansion over 300,000 SF Tenant Representation 164,000 SF Tenant Representation 20,000 SF Tenant Representation through the Power of Education two years. Today, Biocom is seen as the premier life science advocacy organization 21 Biocom Bay Area: Exploring Life Science in California by any significant measure, including membership size, breadth of Opportunities in China programming, number of office locations and staff, savings for our members, and most 23 Biocom LA: The Future’s So Bright For Life importantly, our unequalled track record in accelerating the success of our life science Sciences in LA, We Have to Wear Shades community. As your president and CEO for more than 18 years now, I have been 25 Biocom Institute: 1,000-Times Stronger: Our Commitment to Workforce Development privileged to work with the most talented Board of Directors and employees to develop 26 What’s New on the Completely Revamped and pursue the strategies that have guided us to the position that we enjoy today. Biocom Website At the same time, I continually reflect on how we have stayed true to our roots and 27 Capital Development: The Keys to Success: maintained the pillars of the association that we established long ago—advocating for Relationship Building our industry, building networks, raising capital, providing key business services and 29 Biocom Purchasing Group: 1,000 Members building the professional workforce. Means Millions More in Savings In the beginning, Biocom was the face of a new industry in San Diego, with the promise BIOLABS ARCTURUS THERAPEUTICS HERON THERAPEUTICS 30 Guest: Get a Jump Start on Tax Reform of creating a new arm of the economy in the field of therapeutics and device development. 16,000 SF Tenant Representation 10,000 SF Tenant Representation 28,200 SF Tenant Representation 31 Biocom Institute: STEM In The Community - Our first members came together as a small group of company CEOs and service providers 10 Years in the Making looking to network together both to explore opportunities to create business partnerships, Events: It Takes More Than Home Runs to 32 and to work toward solving policy issues of common interest at the local level. These CEOs Succeed CLIENT TESTIMONIALS and service providers had come from Biocom’s predecessor organizations, the Biomedical 33 Members in Action Industry Council and the San Diego Biocommerce Association. This unique mix of business 38 Biocom Board of Directors executives laid the foundation for the Biocom that exists today, albeit larger in membership “They helped Takeda to “C&W Life Sciences was a great “They are the “go to” real 39 Biocom Committee Leadership and broader geographically. This unique structure continues to allow us to build the understand the market, carefully partner for our company. Their estate team for the life science 39 Committee Corner: CRO Committee consider all viable alternatives, specialization in life sciences real industry. I trust them and highly collaborative relationships for which we are known. 40 Biocom Premium Member Spotlights and arrive at a custom solution estate enabled us to get great recommend them.” When I came to the association, San Diego had just been chosen to host the BIO Biocom Membership with exceptional economic and space with flexible terms for our 42 Annual Convention of 2001. It was our opportunity to build a relationship with our Magda Marquet other lease terms.” corporate headquarters.” national organization while showcasing our strength in life science for the first time Ph.D. Co-Chairman & Founder David Weitz Joe Payne Althea Technologies to the world. After a successful BIO, our membership of about 300 companies and Head of Takeda California and President & CEO firms recognized that we needed to expand our advocacy efforts to Sacramento and Global Research Externalization Arcturus Washington, DC. This occurred concurrent with the expanding presence of larger EDITOR: Lauren Panetta pharma and medical device companies in San Diego. They immediately saw our numerous beneficial services as an important aspect of Biocom’s value proposition. BRENT JACOBS COPY EDITOR: Julie Ames And we expanded our team accordingly, bringing in the expertise needed to operate [email protected] DESIGN & LAYOUT: Lauren Panetta within those spheres. With the growth of jobs in our industry at the time, we also CA License No. 791657 LEADING TENANT responded to our members’ call for more certificate and degree programs in the biomedical sciences and in business. The goal was to create a larger employment pool, GREG BISCONTI VOLUME 26, ISSUE 3 [email protected] and hence we created the Biocom Institute, our professional affiliate. We realized the ADVISORS FOR THE CA License No. 1167920 WWW.BIOCOM.ORG TED JACOBS Continued Pg 2 LIFE SCIENCES [email protected] CA License No. 1855220

INDUSTRY (858) 452-6500 Biocom LifeLines Fall 2017 1 WELCOME CONT.

importance of developing a “home-grown workforce” of employees within the community who would be trained and employed here. Very quickly, our membership ranks swelled. By the time of the 2008 recession, Biocom had a membership of 500 firms. We recognized that fueling the continued growth of our industry during challenging economic times required new initiatives. Consequently, we placed greater strategic focus on helping our members obtain the funding that they needed to do their research and development. This led us to create our capital formation initiative, first as an annual venture capital conference and later as our Global Partnering Conference. We also launched a series of venture and pharma partnering days. Another result of the recession was a contraction in large pharma and biotech staffing, which ultimately led us to create our CRO group, comprising a talented pool of individuals and firms that could provide expert consulting services to our companies here in California and throughout the world. And, we continued to grow. More recently, we have seen continued membership growth in each of our key clusters: in our long-time home base of San Diego (known for its innovative company creation), in our new hubs of Los Angeles and the San Francisco Bay Area, and overseas in Japan, where we established an office in Tokyo just last year. With close to 1,000 members, our greatest strength today is our ability to bring experienced best practices to cluster- building, and to connect those clusters here and around the globe. But I would like our members to know that Biocom is still an association that is owned by its members. Our success is due to the loyal financial support and engagement of our members. Our vision is and always has been, to be best-in-class for our members, providing unparalleled advocacy and business services. As you read through this issue of LifeLines, I know you’ll appreciate why Biocom at 1,000 members strong has a firm foundation beneath its feet that will provide solid direction for growth of our industry today and long into the future.

Now you can follow us on social media for the latest life science news in LA, San Francisco, and San Diego!

Biocom: @biocomCA LA: @biocominLA SF: @biocominSF

2 Biocom LifeLines Fall 2017

COVER STORY By Kelly Quigley, Canale Communications Strength in Numbers Why 1,000 Biocom members really matters for the success of our industry, and for every individual and company who is part of our fabric.

Biocom will hit a major landmark before the end of 2017. It’s the ground working to influence legislation, advocate favorable a milestone that few would have predicted more than 22 years policies, negotiate competitive purchasing programs and foster ago, when our association was just beginning to affect momentous new business opportunities for its members. change in San Diego — yet one that will embolden our industry’s “Whether it’s fewer than 100 or more than 1,000, our team will ability to make an even greater impact in the decades to come. always have a singular focus: delivering unequalled value to our Biocom will soon reach 1,000 member companies, together members across the state,” says Joe Panetta, president and CEO encompassing more than 250,000 industry professionals who are of Biocom, who’s seen the organization grow tenfold during his 18 connected to our hubs in San Diego, Los Angeles and the San years of leadership. “No matter their size, scale, scope or location, Francisco Bay Area. That’s more than any other life science trade we work to accelerate success for our members as they seek to association in California, and puts Biocom’s size in the same improve human health.” ballpark as even the national industry organization for biotech. To put it into perspective, here are five top reasons that a Thoughtful, planned growth means quantity can correlate with 1,000-company membership makes such a difference for every quality, and that’s quite meaningful for an organization that’s on individual who is part of the Biocom community.

4 Biocom LifeLines Fall 2017 COVER STORY

More Attention From Policymakers events that draw a variety of member segments. “It creates an Biocom was founded in 1995, built around an alliance of leaders environment of cross-disciplinary collaboration,” Exner says. who sought to educate local government officials about the biotech Networking is important everywhere, of course, but it’s especially industry’s need for water amid a regional drought in Southern so in life science markets such as Los Angeles and San Francisco California. Its legislative scope has expanded vastly over the —cities where life science markets are geographically spread apart. years, representing the life science industry’s interest on issues “As we all know, no one can make it in this industry by that span regulatory taxes, regional infrastructure and government themselves,” says Dina Lozofsky, executive director of Biocom’s grant-making. Los Angeles operations. “By connecting our L.A. members into the At any moment, Biocom is actively monitoring critical issues broader Biocom membership, we are helping them find potential affecting life science companies. In 2017, staff kept a keen eye partners, investors, mentors and service providers we all need.” on seven pieces of U.S. legislation and a whopping 64 pieces of state legislation. Along with its growing membership comes greater respect in Major Discounts, Savings, and Leverage Across the Board regional government, the State Capitol and in Washington, D.C., What do consumables to chemicals, fume hoods and cell lines have says Biocom Chief Policy Officer Jimmy Jackson. With members in common? They are from Fisher Scientific’s world’s-largest catalog throughout the state, and especially in each of the large population of products and services available at exclusive discounted pricing centers, Biocom is able to successfully engage more policymakers for Biocom members. In just over a year’s time, nearly 400 member as partners in growing the life science economy. companies have chosen the Fisher contract with its breadth and “We hope to help unify the California delegation and strengthen depth of solutions to achieve over $50 million in savings. California’s economy on issues such And that’s on top of the as the importance of strong patent significant Biocom Purchasing protection,” Jackson says. “Biocom Group savings from life science will be able to communicate to “AS WE ALL KNOW, NO ONE CAN industry service providers elected officials from Los Angeles, such as Cultura, Office Depot Orange and San Diego Counties, MAKE IT IN THIS INDUSTRY BY and UniFirst. On average, and the Greater Bay Area how such THEMSELVES. ” members save 15-25 times protections are critical to company their membership dues through value and to the very existence of the - DINA LOZOFSKY, EXECUTIVE DIRECTOR, the Biocom Purchasing Group life science clusters in and around BIOCOM’S LOS ANGELES OFFICE contract offerings. their home districts.” “From a negotiating perspective, the difference between even 600 members Connections at Every Turn and 1,000 members is night and day,” says Rick Fultz, who’s on It’s not just shaking hands. It’s forming alliances, making the front lines of contract negotiations as managing director of friends and finding new star employees (or employers). Biocom the Biocom Purchasing Group. “A large pool of companies helps orchestrated more than 150 networking and educational events everyone. It provides life science companies of any size with more in the past year throughout the state, says Shaye Exner, senior leverage, more partnerships, more of what every member needs to director of conferences and corporate sponsorships. succeed.” “Our events have evolved over the past 15 years based on the Meanwhile, members have embraced Biocom’s health benefits growth we have seen—and not just growth in our membership solution by signing up for Beyond Benefits, with over 250 enrolled numbers, but growth in the diversity of companies we represent,” life science companies representing over 20,000 employees and Exner says. dependents in California. With a 96 percent client-retention average, The increased membership growth, combined with the greater and a 2017 decrease in rates, the program boasts choice and stability mix of companies and industry representation, has created a critical at an average of $1,000 in savings per employee per year. mass that’s enabled Biocom to branch out from all-inclusive events “At 1,000 members strong, we carry a big stick at the (think regular breakfast meetings that attracted 300-plus people) negotiating table with current and potential suppliers,” says Fultz, to more frequent, customized events that specialize in serving the who also serves as Biocom’s chief business officer. “Our ability to needs of various industry specializations. negotiate bottom-line-changing discounted contracts on behalf of That said, Biocom finds there’s still a lot of value in holding our members is now strengthened tenfold.”

Continued on page 7

Biocom LifeLines Fall 2017 5 Experience How Everything We Do [ Has A Single Focus - Your Success]

Providing aaest services to a wide variety of public companies, early-stage and growing private companies.

We are one of the leading providers of accounnng services to Southern California’s Technology & Life Sciences industries - focusing on private companies preparing to go public or be acquired.

www.mhmcpa.com | 858.795.2000

Contact: David Diamond Technology & Life Sciences Praccce Leader [email protected]

MHM (Mayer Hoffman McCann P.C.) is an independent CPA firm that is a member of Kreston Internaaonal, Limited, a global network of independent accounnng firms. COVER STORY

Undivided Attention from Investors & Potential Partners Consider this: Five years ago, in 2012, the Biocom Global Life Experience How Everything We Do Science Partnering Conference fostered 139 meetings over the And that’s not all… Has A Single Focus - Your Success course of the two-day event. This year, that number more than More reasons we’re stronger [ ] doubled, with 375 meetings between life science executives, bankers, venture capitalists and business development with 1,000 professionals from the leading pharmaceutical and biotech companies around the globe. “There is no question that our Increased efforts to enhance the workforce increased membership is what has made this annual conference of the future. For nearly 10 years, Biocom’s one of the most productive and beneficial of the year for the 501(c)(3) organization, the Biocom Institute, member companies of Biocom,” said Jennifer Landress, senior has ensured the sustainability of this vital vice president and chief operating officer. Recent partner day industry and inspired the STEM leaders of attendees include Eli Lilly, GSK, Vertex, Illumina and Bristol- tomorrow through student and teacher STEM Myers Squibb. outreach, entrepreneurial and workforce In addition, Biocom continues to expand its capital development programs, and veteran-focused development efforts, working to connect members with funding mentorship programs. from venture capitalists and other sources—both public and private. Among the many association resources centered on More international ties. capital development, Biocom helps coach companies on how Biocom’s size has been one determining to set themselves apart from the crowd and unequivocally factor in the partnerships it has forged with demonstrate they have the expertise, team and assets to meet industry groups in Japan, China, the United today’s stringent investment criteria. Kingdom, France and Australia. For companies in California, this means easy access to new markets, new ideas and new opportunities A Thriving CRO Ecosystem across the globe. Biocom launched its CRO initiative 10 years ago, in an effort to put San Diego on the map as a destination for outsourcing. Since Year-round discounts on an individual then, outsourcing demand has exploded in our industry—and so level. CorePower Yoga, The San Diego has Biocom’s CRO membership. Museum of Art and Enterprise Rent-a-Car are Today, Biocom has more than 100 CRO/CMO member- among the 45 (and growing) participants of the companies, each one providing essential support to California’s Biocom Boost program, which gives employees life science ecosystem. Biocom has responded to this growth of Biocom member companies access to with a new series of CRO-specific events designed to help these exclusive, year-round discounts and benefits at members overcome common hurdles and expand their businesses, Providing aaest services to a wide variety of many popular businesses across California. both through education and networking. public companies, early-stage and growing private companies. The centerpiece of Biocom’s CRO community is a website visited Celebrating future generations. New in frequently by members around the world, www.BiocomCRO.org. 2017, Biocom launched the Life Science Young The site serves as a tool for life science companies to identify Leaders program. Geared toward scientists, We are one of the leading providers of accounnng services to a CRO that fits their specific project needs, with a directory entrepreneurs, and recent graduates seeking to that encompasses services for every stage of drug development. Southern California’s Technology & Life Sciences industries - focusing on network and be inspired, the program energizes In the resources section, CRO members can post white papers, the next generation of biopharmaceutical private companies go public be acquired preparing to or . presentations, and press releases; a blog provides a forum for industry leaders. members to highlight notable activities. www.mhmcpa.com | 858.795.2000

Contact: David Diamond Kelly Quigley is Content Technology & Life Sciences Praccce Leader Director at Canale [email protected] Communications Inc.

MHM (Mayer Hoffman McCann P.C.) is an independent CPA firm that is a member of Kreston Internaaonal, Limited, a global network of independent accounnng firms.

Biocom LifeLines Fall 2017 7 GUEST By Erica Ramos, MS, LCGC Associate Director, Market Development Clinical Head, Precision Health & Screening, Illumina, Inc. Genetic Counselors in Biotech: Bringing the Clinic to Industry

As the availability and applications of genomic testing in Genetic counselor Christin Coffeen is part of the Market healthcare has expanded, so have the number of biotech com- Development team within Illumina’s Clinical Genomics Group panies and laboratories offering products and services in this focusing on Europe, Middle East and Africa. She told me, “Aside arena. In the past 10 years, this has coincided with an influx of from the obvious breadth of genetics education that one receives genetic counselors into industry. Genetic counselors (GCs) are cli- in a genetic counseling program, one unique component of this nicians with advanced training in genetics, genomics and coun- training is the psychosocial/counseling courses – whether it be seling. There are more than 4,000 certified genetic counselors in understanding different cultures and different personalities, the United States. Historically, most GCs worked in clinical care explaining complex information in simple terms, or listening to and saw patients to evaluate family health history, counsel on risk and assessing the needs of an individual. All of these skills have of genetic diseases, discuss genetic testing options and provide proved immensely valuable in my role where I present complex psychological and social support, but the expansion of clinical genetic information to international clinical customers (labs genomic applications has led many more genetic counselors to and healthcare providers), listen to the concerns and assess the seek opportunities within industry. needs of these international clinical customers, and represent In 2002, only 14 percent of respondents to the National the clinical voice of our customers to my Illumina colleagues.” Society of Genetic Counselors (NSGC) Professional Status Diana Tuman, who is a genetic counselor and Senior Manager, Survey said that they didn’t see patients. In 2016, that number Product Marketing echoed Christin and Lindsey. “Having a GC increased to 31%. I attribute this change to the many genetic background provided me with a great genetics foundation and counselors who have demonstrated that our deep scientific and understanding of the clinical space, patient challenges as well medical knowledge and our communication and counseling skills as clinician pain points. This allowed me to not only provide sci- are valuable across industry, research, education, management entific-based content, but also help in the launch of new genetic and entrepreneurship. Genetic counselors’ training, ability to products and services that are most relevant to Illumina cus- translate complex genetic concepts and deep understanding of tomers and downstream patient care.” the clinical applications of genomics has not gone unnoticed I may be a bit biased, but my experience suggests that genetic outside of the clinic and today genetic counselors hold diverse counselors add value across specialties in a biotech company. positions across industry. When you can bring the voice of the clinician, the patient and So what are genetic counselors doing in biotech? At Illumina, their family further up the development pipeline, it supports the we have 17 genetic counselors working in multiple areas of the development of the best and most clinically applicable products company. I asked a few of our genetic counselors to share how and services. To learn more about genetic counseling visit their training prepared them for these varied roles. the National Society of Genetic Counselors consumer page at In our Medical Affairs team, genetic counselors focus on multiple aboutgeneticcounselors.com. areas of education, especially for clinicians. Genetic counselor and Senior Manager of Medical Education Lindsey Fosler said, “I rely heavily on my training as a GC. In my training, I learned how to effectively communicate and educate both healthcare providers Erica is the Associate Director of and patients on complex concepts such as genetics.” Market Development and Clinical Head Many of Illumina’s genetic counselors, myself included, work in marketing and market development. GCs have a high degree of Precision Health & Screening for of market awareness and extensive networks in the clinical Illumina, Inc. genomics space. Our GCs also support and enable research that can answer critical questions about the utility of testing.

8 Biocom LifeLines Fall 2017 ASAP

ACCELERATED STRAIN ADVANCEMENT PLATFORM

+ NON-GMO PROCESS

+ INCREASED YIELDS

+ IMPROVED ECONOMICS

www.nucelis.com On-Time, On-Temperature™ SAVE TIME. SAVE MONEY. Get Your Clinical Supply Strategy Right the First Time.

Find out how with our guide: What does your clinical study design tell you about your clinical packaging needs

DOWNLOAD AT: climb.SherpaClinical.com/clinical-supply-strategy

SherpaClinical.com blog.SherpaClinical.com (858) 997-1490

6166 Nancy Ridge Dr. San Diego, CA 92121 PUBLIC POLICY By Jimmy Jackson, Senior Vice President & Chief Policy Officer, Biocom

On-Time, On-Temperature™ 1,000 Members Packs a Policy Punch

SAVE TIME. SAVE MONEY. “I’m representing Biocom’s one thousand members from educational briefings about the use of genomics in oncology, federal Get Your Clinical Supply Strategy Right the First Time. clusters throughout the state of California.” investment in biomedical research, and drug pricing, and hosted a It’s hard to fully wrap one’s head around what representing 1,000 reception on Capitol Hill with the Healthcare Institute of New Jersey members means. Most of all, it is a huge responsibility. Our team and Congressional Life Science Caucus. must understand the unique needs of each of the business sectors On the state level, this summer was one of intense activity. Bills of Biocom’s membership, and we have to stay aware of how those mandating advanced notification of drug price increases (SB 17) needs might shift between the geographic regions. In the policy and significantly narrowing how patient prescription drug price arena we have always prided ourselves that a local government issue assistance programs may be conducted by manufacturers (AB 265) (water availability) was a key driver behind Biocom’s founding. were considered. Although versions of both bills were signed into On federal and state issues, we now represent member companies, law by Governor Brown, Biocom played a key role in an industry both small and large, spanning the breadth of the state, especially coalition which secured significant changes in both bills as they in each of the large population centers. We can discuss how an moved through the process. Member activation on the price noti- issue such as proposed cuts to the NIH will affect everything from fication legislation, including a BIO small company sign-on letter companies to university-based research in the Greater Bay Area, Los that Biocom circulated to our small board level companies, was key Angeles, Orange and San Diego Counties, and the expanded effect to securing these changes, as SB 17 was one of the most heavily that it will have in the service economy of each of those regions. lobbied and contentious bills this year. Biocom worked very closely The knowledge bank that 1,000 members gives Biocom is also with member companies and our industry partners at BIO, PhRMA invaluable in establishing best practices. As we continue to build and CLSA to attempt to defeat or amend these bills. on success and partnerships at the local government level, and add In regional efforts, roundtables were held for Biocom members to examples of those successes, this sends an important message with Mayor Kevin Faulconer of San Diego and Mayor Eric Garcetti across the state. It reinforces the message among policy makers of Los Angeles. Biocom partnered with the California Biotechnology that Biocom is an organization that will help them demonstrate their Foundation for very well received “Biotech 101” sessions with staff seriousness about helping business succeed and creating local jobs. members of elected officials in Los Angeles and San Diego. Our Bay Over the past few months, Biocom’s Washington office has focused Area member engagement continued with a Sustainability Workshop on the repeal of the medical device tax. The 2.3 percent excise tax in September, while San Diego members have benefitted from an Find out how with our guide: on the sale of medical devices has been suspended by Congress for informational series (complete with certification) focusing on life two years, ending at the end of this year. Following Congress’ inabil- science company needs developed by SDG&E. What does your clinical study design ity to pass legislation repealing the Affordable Care Act (ACA), which Finally, Biocom thanks the almost 100 elected officials and would have included repealing the medical device tax, Biocom Biocom members who came out for our Biocom PAC Annual Elected tell you about your clinical packaging needs redoubled its efforts to bring elimination of the device tax to the Officials Reception at the beautiful i3 campus of Illumina in San forefront. The Biocom action center on our website features a medi- Diego (view pictures in the Members in Action section). Our heartfelt cal device tax action alert, which enables you to write to your elected thanks to Signature Sponsor Genentech and Host Sponsor Illumina officials to urge them to support a full repeal of the tax. for their continued support of this event. DOWNLOAD AT: Earlier this summer, Congress passed legislation to reauthorize the Food and Drug Administration (FDA) user fee agreements. Timely climb.SherpaClinical.com/clinical-supply-strategy reauthorization of the agreements was an important victory for our industry because it will ensure that the FDA has the resources it Jimmy Jackson is the Senior Vice President needs to review products faster and improve the pre- and post-mar- and Chief Policy Officer for Biocom. ket approval process, among others. Lastly, Biocom continues its He oversees government affairs and public policy for the organization. SherpaClinical.com blog.SherpaClinical.com (858) 997-1490 efforts to educate Congressional leaders and their staff and connect them to industry. In the past four months, we have organized several 6166 Nancy Ridge Dr. San Diego, CA 92121

Biocom LifeLines Fall 2017 11 FEATURED STORY By Kelly Quigley, Canale Communications

R E D N U

The Catalyst Awards, now in their second year, honor life Curious. Creative. Undeterred. science professionals40 in Southern California who have made their mark on the industry before the age of 40. These women and The 2017 Life Science Catalyst Award winners are men are applying their unique perspectives and skillsets to solve bringing fresh thinking to some of health care’s colossal problems that affect people around the world, with goals to diagnose disease faster, end cancer recurrence, help doctors biggest problems. make sense of big data…and the list goes on. And even though they can’t remember the birth of biotech, Life science industry veterans remember what the world was like they’re solving these major problems with the same level of passion before biotechnology redefined the way we solve disease and and drive that have been hallmarks of the industry from the start. other global challenges. But for the winners of this year’s Biocom Evaluated by a committee of executives and board members Life Science Catalyst Awards, biotech has been around for at from Biocom; thought leaders in the Los Angeles life science least as long as they have. industry; and members of the San Diego Venture Group, this They were born during the industry’s formative years, starting year’s winners represent the best of emerging life science innova- in the late 1970s, and earned their undergraduate degrees around tors across Southern California. These are the young executives, the same time that the human genome was first sequenced. And scientists and scholars who will take us to tomorrow. today, they are the young leaders shaping the industry’s future.

ENABLING FASTER HEALTHCARE DECISIONS Francie Barron, Ph.D., 36 | Vice President of Biology and Regulatory Affairs, Nanomedical Diagnostics

Francie, the senior biological and medical sciences expert at Nanomedical Diagnostics, has been molding the company’s success for more than two years, working with teams to develop inno- vative new products that enable cutting-edge life science research, drug discovery and portable diagnostic and health-monitoring platforms. Her goal is to help healthcare providers make clinical decisions in a timely fashion so clinical outcomes improve. “This looks like creating point-of-care testing that can diagnose infectious disease earlier and track how the body metabolizes drugs to give real-time information to the healthcare provider,” says Francie, who completed her post- doctoral fellow at Stanford University School of Medicine, performing research using induced pluripotent stem cells. Francie also works closely with local high school science educators to expose kids to STEM careers, and has helped create a robust internship program with college students. When she’s not in the office, she’s often in the water: “I’m an active scuba diver, and the deepest dive I ever did was a wreck dive at Australia’s Great Barrier Reef...40.1 meters!”

12 Biocom LifeLines Fall 2017 FEATURED STORY

GETTING TO THE HEART OF THE MATTER Karen Christman, Ph.D., 39 | Professor of Bioengineering, University of California, San Diego; Scientific Co-founder, Ventrix Inc.

Karen is working on many fronts to improve quality of life for cardiovascular disease patients using biomaterials-based regenerative medicines. A prolific scientist in the field of tissue engi- neering and regenerative medicine—with more than 70 publications and 100 invited talks to date—Karen also is a visionary entrepreneur and devoted mentor to dozens of current and former students at UCSD. As co-founder of Ventrix, Karen guided initial scientific research for a novel biomaterial scaffold and advanced it into a product, VentriGel, that’s now being tested in the clinic for cardiac repair. Her work has been recognized by many well-known institutions including the National Institutes of Health, Wallace H. Coulter Foundation, the American Heart Association and the Tissue Engineering and Regenerative Medicine Society.

INNOVATING BIOTHERAPEUTICS AT FULL FORCE Brendan Eckelman, Ph.D., 39 | Co-founder, Chief Operating Officer and Vice President of Biotherapeutics, Inhibrx LP

Brendan is co-founder of the small biotech company Inhibrx, which is quickly developing drugs that span oncology, infectious disease and inflammatory conditions. He leads therapeutic development and scientific operations, along with holding critical responsibilities in corporate strategy execution. That’s no small task considering Inhibrx plans to file seven INDs in the next 18 months. After earning his Ph.D. in molecular pathology from UCSD School of Medicine, Brendan performed graduate research at Sanford Burnham Prebys Medical Discovery Institute and before joining the Genomics Institute of the Novartis Research Foundation as a research investigator. Now at Inhibrix, he’s focused on keeping the innovation engine churning, free of bureaucratic barriers. The end goal: “Annually advance multiple new therapeutics into clinical development, which are capable of surpassing the ever-raising efficacy bar.”

TACKLING HEALTH CARE CONTROVERSIES HEAD-ON Dov Fox, J.D., 35 | Professor of Law, University of San Diego School of Law

Dov knows the sticky issues of biotech like no one else. “My writing and teaching in law and bioethics tries to make progress on the controversies of our time and the challenges that lie ahead, from health care reform and translational medicine to brain imaging and gene editing,” he says. The Yale Law School grad publishes his opinions in a range of publications and actively influences policy through submissions of governmental agency comments and amicus briefs, frequent op-eds and speeches on biotech and bioethics. Dov also serves as director of USD’s Center for Health Law Policy and Bioethics, which he was active in found- ing with Stephen C. Ferruolo, the law school dean. “Central to the success of USD’s Center for Health Law Policy & Bioethics are partnerships among dozens of leading institutions of research, innovation, and practice,” he says.

Biocom LifeLines Fall 2017 13 FEATURED STORY

ENDING CANCER RELAPSE AND RECURRENCE Zachary Hornby, M.S., MBA, 38 | Chief Operating Officer, Ignyta Inc.

Ignyta, as a precision medicine oncology company, is trying to eradicate residual disease in defined cancer populations. And Zach is one of its secrets weapons. “I’m personally interested in trying to help the company achieve its goal while providing a work culture that makes Ignyta a fun, meaningful and fulfilling place to work,” he says. He wants employees to “feel good about not only what they did that day, but also how they did it and who they did it with.” His approach seems to be working, as he has helped the company gracefully scale from fewer than 10 employees to a public company with more than 110 employees globally. Zach also leads the global development team for the company’s lead drug candidate, entrectinib. Prior to his current role, Zach excelled at Fate Therapeutics, Halozyme, Neurocrine Biosciences and other biotech companies. “I like the collaborative spirit and positive energy in SoCal,” he says. “People in San Diego seem to love living and working here, and therefore bring positive energy to both components of their lives.” In his free time, Zach is working towards his goal to visit every country in the world. “To date, I’ve visited 102 countries on six continents.”

CREATING THE NEXT GENERATION OF WEARABLES Patrick Mercier, Ph.D., 32 | Assistant Professor, Electrical and Computer Engineering, University of California, San Diego

As principal investigator of UCSD’s Energy-Efficiency Microsystems Lab, Patrick leads a research team that’s inventing and developing miniaturized electronic systems that interact with the body in new and interesting ways—for example, by measuring glucose levels in sweat or monitoring neural tissues at very high spatial resolutions. “One of the big challenges we are trying to address is building more functionality into wearables,” says the MIT grad. “Current wearables offer an exciting look into continuous, real-time activity of a user; however, this information is not that useful clinically.” He’s changing that. With physiochemical sensors, wearables offer a more comprehensive look into real-time wellness. Patrick says there’s no better place to be for his research than San Diego. “The life sciences field is not only very strong, but the high-tech wireless industry also has a big footprint,” he says. “Southern California is well positioned to be at the forefront of these intersecting industries.”

REVERSING GENETIC DISEASE WITH RNA David Nelles, Ph.D., 28 | Chief Technology Officer & Co-founder, Locana Inc.

Is it possible to reverse genetic disease by targeting RNA? That’s what David is trying to find out. “Decades of effort have culminated in genome engineering, but many genetic diseases are best addressed on the level of RNA rather than DNA,” he says. In this new field of transcriptome engineering, David is already a leader, having been part of the team that developed one of the first means to target RNA in living cells using CRISPR. His groundbreaking work, which made headlines across the U.S. earlier this year, started in the UCSD School of Medicine and continues now at Locana, a company he co-founded. “UCSD has been very supportive and integral to our efforts to translate science into treatments for human disease,” says David, whose educational background includes material science and engineering.

14 Biocom LifeLines Fall 2017 USING WHOLE-GENOME SEQUENCING TO SOLVE RARE-DISEASE MYSTERIES Ryan Taft, Ph.D., 39 | Senior Director, Scientific Research, Illumina Inc.

Children with rare genetic disorders often wait five to seven years in the U.S. and Europe before receiving a definitive diagnosis. That’s not acceptable to Ryan, an entrepreneurial scientist with a doctorate in genomics and computational biology. “My goal is to completely eliminate this diagnostic odyssey,” he says. Working with Illumina, he wants to make whole-genome sequencing the standard-of-care for every child who would benefit from it. Ryan has helped Illumina expand its iHope philanthropic program, which has already donated whole-genome sequencing services to more than 100 families in need of answers, and he’s active with multiple rare disease organizations worldwide. “I grew up here in San Diego, and it is strangely delightful to have moved back after many years away,” Ryan says. “I never would have thought San Diego would become one of the hottest spots on the planet for biotech, and that I would be a small part of it.”

TRANSLATING ACADEMIC DISCOVERIES INTO CLINICAL RESULTS Matt Tremblay, Ph.D., 37 | Vice President, Business Development, The Scripps Research Institute; Chief Operating Officer, California Institute for Biomedical Research

Matt is working to speed the development of life-saving medicines and change the way we think about funding nonprofit research. The chemist was among the first employees to join Calibr in 2012, as a principal investigator seeking new therapies for metabolic, cardiovascular and autoimmune diseases. But his business aptitude gained attention from the top ranks, and he was soon asked to play a more central role in operations. Recently promoted to COO at Calibr, Matt has been instrumental in establishing collaborations with organizations such as BMS, Pfizer, Wellcome Trust and The Bill & Melinda Gates Foundation. He has helped Calibr quickly become one of the most well-known translational research institutes in the world; and now, his new dual role at TSRI is helping to set a new standard for collaborative research. “I like the collegial nature of the San Diego life sciences scene,” Matt notes. “I’ve had the privilege of meeting people who were wildly successful in their own pursuits, but who engaged me as a colleague, offered advice freely and took genuine interest in what we were doing.”

TAKING L.A. RESEARCH FROM LAB TO MARKET Thomas Lipkin, Ph.D., 37 | Head of New Ventures, University of California, Los Angeles Technology Development Group

Thomas has his finger on the fast pulse of L.A.’s biotech startup scene. Through his role at UCLA, he ushers early-stage academic research from bench to market, requiring him to work closely and productively with UCLA faculty, graduate students and post-docs. His New Ventures group also provides services through its “Startup-in-a-Box” program, which supports portfolio companies that have licensed intellectual property from UCLA; offerings include legal, insurance, banking and even human resources. “The Milken Institute recently ranked UCLA No. 1 nationally in our number of startup companies, which speaks to the entrepreneurial nature on campus and helps seed the future of biopharma here in L.A.,” says Thomas, who has a Ph.D. in cell biology and pathology. Thomas says he’s on a constant hunt for talented entrepreneurs and consultants for UCLA projects. “While building a stronger life science community here in L.A. is challenging, I’m excited to know there are talented and similarly-minded people here,” he says.

Biocom LifeLines Fall 2017 15 FEATURED STORY

HARNESSING AI TO HELP DOCTORS ACT ON BIG DATA Yan Liu, Ph.D., 38 | Associate Professor, Viterbi School of Engineering, University of Southern California

Yan is developing novel machine learning models that help the doctors decipher big data so they can provide better care to patients. “I feel very fortunate to be at a unique intersection between artificial intelligence and life science,” says Yan, who pioneered fundamental technologies in machine learning for health care, including innovations for improved ICU care, cancer care and drug-intake monitoring. She currently works closely with Samsung to develop deep learning solutions for new-generation smart care of diabetes patients; her lab will help create wearable health devices with artificial intelligent technologies. She also holds six patents as outcomes of her research work, with four more patent applications in review. Yan says her best inspiration is a very special human: “Raising my daughter teaches me a lot about how human beings learn languages, acquire knowledge and socialize with others, which serves as great guidance for me to develop more effective machine learning models.”

DEMOCRATIZING BIOMEDICAL DIAGNOSTICS Aydogan Ozcan, Ph.D., 38 | Chancellor’s Professor at University of California, Los Angeles; Professor, Howard Hughes Medical Institute

Aydogan, armed with a doctorate in electrical engineering from Stanford, is on a mission to “democratize biomedical imaging, sensing and diagnostics tools and technologies so that advanced measurements that are normally restricted to resource-rich laboratories and institutions can be conducted in resource-limited environments, including in developing countries.” Aydogan holds 34 issued patents and more than 20 pending patent applications for inventions in telemedicine, mobile health, nanoscopy, wide-field imaging, lensless imaging, nonlinear optics, fiber optics and optical coherence tomography. Notably, he pioneered lightweight, 3-D-printed smartphone attachments that can diagnose diseases such as malaria and HIV and detect pathogens in water. These mobile devices are portable and cost-effective, making them practical for use in biomedicine as well as environmental monitoring in rural and resource-poor areas.

ADDRESSING AN OVERLOOKED EPIDEMIC IN WOMEN’S HEALTH Tanya Petrossian, Ph.D., 33 | Chief Executive Officer, EndoCyclic Therapeutics; Principal, Building Block Advisory Group

Los Angeles Mayor Eric Garcetti recently named Tanya as one of his three picks for the city’s Entrepreneur in Residence program, but that was far from her most notable achievement of 2017. The UCLA grad also launched EndoCyclic Therapeutics, where she’s working to develop the first non-hormone therapeutic for endometriosis, the leading cause of infertility and disability in women during their reproductive years. Not long after earning her Ph.D. in biochemistry and molecular biology, Tanya dove into key business roles at Affymetrix and Ayasdi in the Bay Area. Since then, she also created Building Blocks Advisory Group, which works with life science startups and investors to bring great ideas to market. Tanya attributes her impressive work ethic to her years as a nationally ranked swimmer, where she learned to set goals, endure tough workouts and “sacrifice fun to reach a bigger goal.”

16 Biocom LifeLines Fall 2017 INJECTING ENERGY AND STRUCTURE INTO L.A.’s BIOSCIENCE CLUSTER Marie Rippen, Ph.D., 30 | Chief Executive Officer, Lab Launch

Marie has been key in developing a vibrant bioscience cluster in the L.A. area. As CEO of a nonprofit known as Lab Launch, she’s helping L.A.’s scientists and entrepreneurs advance their ideas in affordable, high-quality labs, and with access to a supportive innovation community. Marie holds a Ph.D. in genetics and molecular and cell biology, giving her an excellent understanding of what cutting-edge scientists want and need. But she’s proven to also think (and act) like an entrepreneur. Marie is the creator of the Biotech Entrepreneurship Coalition, or BEC, a group that creates new opportunities for young scientists to learn about the real-life challenges and opportunities offered by entrepreneurship. “My central question is: how can we accelerate life science innovation here in L.A.?” she says. “L.A is such a different kind of biotech hub from the traditional model; it’s exciting to see how we can make those differences work in our favor.” Marie also is an avid salsa dancer. “I started in college and danced with a performance team through most of graduate school.”

Science That Inspires The Life Science Catalysts inspire us, but who inspires them? When asked them to name their favorite scientists, here’s a sampling of what they said.

“Marie Curie. She fought to overcome so much to do research in an academic environment that did not encourage women to excel. It is an inspiration and a reminder of how much women have gained in the years since Dr. Curie did her work. I hope to break more ceilings in STEM for more women to succeed by mentoring those just beginning their careers.” — Francie Barron

“Peter G. Schultz [director of Calibr and president and CEO of The Scripps Research Institute]. He is the ultimate no-holds-barred thinker and doer.” — Matt Tremblay

“The famous physicist Richard Feynman. His interest in understanding the underpinnings of the natural world was only matched by his passion for communicating his Marie Curie Marie Curie, née Maria science as broadly as possible.” — David Nelles Sklodowska, was born in Warsaw on November 7, 1867, the “Whichever ancient Greek scientist first posited that the Earth is round because, if not that daughter of a secondary-school individual, I surely would have fallen off the Earth by now during my travels.” — Zachary Hornby teacher. Curie’s early researches were often performed under “Dr. Oliver Smithies. He won the Nobel Prize for genetically engineering mice, but he difficult conditions, laboratory arrangements were poor. also was the first person to develop gel electrophoresis. The story is that he came up with the Overcoming these challenges, idea when watching his mother use starch to iron his father’s shirts. He advanced science in Marie and her husband were many ways.” — Tanya Petrossian awarded the Nobel Prize for Physics in 1903, for their study “Marie Skłodowska Curie. She is the first female Nobel Prize Winner and the first into spontaneous radiation. In 1911, she received a second person who won the Nobel Prize twice, but what strikes me most is her dedication to scientific Nobel Prize, this time in work and her courage as a person in time of difficulties and personal loss.” — Yan Liu Chemistry, in recognition of her work in radioactivity. Vault-Biocom-Ad-Full-Page.pdf 1 10/7/15 6:45 PM

C

M

Y

CM

MY

CY

CMY K Elevate Through Innovative Biopharmaceutical Strategy Vault Bioventures is a San Diego-based, global life science consultancy focused on driving value through innovation & strategic thinking.

We partner with biopharmaceutical companies Clinical Development & Regulatory & healthcare-focused investment capital firms Business Development across all stages of the product life cycle to build the bridge from molecule to brand. Commercialization

CONTACT VAULT & UNCOVER YOUR HIDDEN VALUE TODAY! 855.483.4838 HQ: 12555 High Bluff Dr., Suite 140 San Diego, CA 92130 Web: vaultbio.com

Vault Bioventures is a proud member of Vault-Biocom-Ad-Full-Page.pdf 1 10/7/15 6:45 PM

GUEST By Doug Kaufman, Vice President, Medscape Education

Understanding New Therapies through the Power of Education

Emerging Biotechnology and Biopharma are studies, professional conferences, and contact with pharmaceutical Revolutionizing Patient Care representatives—is decreasing. And while conventional and social It is no secret that the biotechnology and biopharmaceutical media marketing strategies play a role in providing information to industries are the future of personalized health care. Advances in clinicians about the benefits and risks of biotechnology agents, fields such as neurology (e.g., proteomics) and cardiology (e.g., physicians have become increasingly cautious of promotional microRNA-based therapies) are driving predictive, prognostic, tactics. This wariness poses a barrier to knowledge uptake and clin- and therapeutic progress. Innovation has been especially rapid in ical application of emerging and newly-launched biotechnologies oncology, with the development of technologies like genome editing, and agents. next generation sequencing, and cancer immunotherapies based on In contrast, online continuing medical education (CME) is a diverse mutations. demonstrably effective option for preparing physicians to integrate

C Yet while physicians are highly strategic and effective learners, few are currently M equipped to integrate novel discoveries or Y newly-launched biotechnology products CM into clinical practice. This knowledge and

MY skills lag is especially evident in areas such

CY as genomics. Many physicians are frank about their lack of familiarity with genomic CMY testing options or specific indications for K Elevate Through Innovative particular tests; several surveys report that physicians are unable to distinguish between genomic sequencing and array- based genotyping, as well as unprepared to Biopharmaceutical Strategy interpret and utilize genomic information in clinical practice. A recent study found Vault Bioventures is a San Diego-based, global life science consultancy that even among oncologists—a medical focused on driving value through innovation & strategic thinking. specialty with a high proportion of early adopters—at least one third had not ordered We partner with biopharmaceutical companies Clinical Development & Regulatory tests to guide treatment for patients with & healthcare-focused investment capital firms non-small cell lung cancer based on the Business Development tumor’s genetic profile. across all stages of the product life cycle to build the bridge from molecule to brand. Commercialization Physician Exposure to Emerging Biotech is Limited Physicians may be unprepared for the biotechnology revolution for emerging biotech discoveries into clinical practice, as physicians CONTACT VAULT & UNCOVER YOUR HIDDEN VALUE TODAY! 855.483.4838 many reasons. First, there is no standardized approach to educating want high-value education rooted in science, in formats that match their learning preferences. HQ: 12555 High Bluff Dr., Suite 140 San Diego, CA 92130 Web: vaultbio.com physicians on genomics or other biotechnology innovations. Second, many physicians are simply overwhelmed by the volume of new clinical information they must process and evaluate as part of their CME as a Change Agent commitment to ongoing performance and quality improvement. CME is a leading vehicle of knowledge transfer and behavioral Third, physician exposure to new molecule information—via clinical change in clinical settings. Online CME personalizes learning,

Vault Bioventures is a proud member of Biocom LifeLines Fall 2017 19 GUEST CONT. by collecting data about gaps in knowledge and skill through pre- activity assessment of participants, delivering unbiased, scientifically rigorous educational content via formats that are clinically-relevant, interactive and participatory. Regardless of lifecycle stage, this Doug Kaufman is Vice President approach has proven to be especially effective for raising awareness of Medscape Education among physicians about emerging agents and technologies prior to ([email protected]). approval, as well as preparing them to appropriately evaluate inte- gration of novel therapies and interventions into clinical practice post-approval. Notably, physicians value CME because influential educators—like Eric Topol, MD, Professor of Genomics at the Scripps Research Institute and Editor-in-Chief, Medscape—are able to trans- late science into actionable, evidence-based strategies in the clinic.

Case Study: Identifying Gaps and Improving Clinical Impact in an Underdiagnosed Disease State

Prior to the 2016 launch of Nuplazid (pimavanserin), the first drug approved to treat Parkinson disease psychosis (PDP), San Diego-based ACADIA Pharmaceuticals wanted to identify what psychiatrists and neurologists understood about this condition.

Medscape Education measured physicians’ knowledge and skills via a baseline survey (n = 1274). Results showed significant gaps in knowledge about the hallucinations and delusions associated with PDP, as well as low awareness about the effects of standard treatments on these symptoms, and of clinical data regarding new agents. Subsequently, Medscape created a CME curriculum that focused on PDP epidemiology and pathophysiology, disease detection and diagnosis, and medication mechanisms of action.

An outcomes assessment demonstrated that physicians exposed to the education improved their awareness of PDP, and were equipped to use the latest agents for managing Parkinson disease-related psychosis. Biocom Big Data Executive Summit Intersection of Preparing Physicians to Implement Innovation Precision Medicine Healthcare is changing rapidly. The shift toward personalized medicine, grounded in a spectrum of life science technologies from and Oncology genetic engineering, to cell therapy, to DNA sequencing, to pharma- ceutical agents, means that physicians will need to be well informed November 29, 2017 about these discoveries. Independent online CME delivers high-value information to millions of healthcare professionals, and provides an The Alexandria at Torrey Pines unbiased and effective mechanism to not only raise awareness about emerging biotechnology innovations and agents, but also prepare physicians to apply these innovations to clinical practice in ways that improve patient health. BIOCOM BAY AREA By Michelle Nemits, Director of Business Development, Biocom Purchasing Group

Exploring Life Science Opportunities in China

Biocom has a unique position as an international ambassador • Dr. Jeff Cox, Faculty Director and Professor, UC Berkeley for the California life sciences industry. We have methodically Center for Rare and Emerging Diseases developed our advocacy for investment in California, as well • Annie Lin, Program Coordinator, UC Berkeley Center for as our efforts to build bridges between our members and life Rare and Emerging Diseases science clusters around the globe. Our strategic partnerships • Michelle Moskowitz, Director of Advocacy and in Japan, the UK, France and Australia have yielded numerous International Relations, UC Berkeley Office of opportunities for our members to connect to international Government and Community Relations sources of investment, collaboration and commercialization. China has been an area of exploration for a number of • Akash Bakshi, Assistant Director of Technology Analysis years, with Biocom CEO Joe Panetta visiting several times and Marketing, UC Berkeley to assess the life science ecosystem, build partnerships with • Paul Gadiock, Senior Attorney, Arent Fox biotech clusters in several Chinese cities, and see how we might connect to the potentially huge opportunities available Each of us was there to explore opportunities for our there. Our CEO also keeps a keen eye on the necessary market respective companies or institutions; some for collaborations on maturity that enables responsible technology, manufacturing and effective collaboration with or research, and some China. In September, I had the for investment or other opportunity to participate in partnerships. According to the Bay Area Council’s (BAC) “CHINA HAS THE SCALE, KNOW-HOW Dr. Keasling, “China is the Sixth Annual Life Science largest energy market on Delegation to China. I got a AND AMBITION TO BE A WORLD LEADER the planet and a place that first-hand glimpse into the life IN MANY INDUSTRIES AND HAVE PUT is embracing renewable science landscape in the cities energy. As such, China is of Shanghai, Hangzhou and LIFE SCIENCES AS A PRIORITY. ” an important market for JBEI’s technologies.” Nanjing. - DR. DRORY OF TWIST BIOSCIENCE “In 2007, the Bay Area We frequently hear that Council established a business the Chinese economy development platform between is booming—even when China and San Francisco/Silicon it’s growing slower than Valley with the goal of accessing the growing markets of China expected. But seeing first-hand mile after mile of newly-built and encouraging investment into our region. More than 300 skyscrapers and apartment buildings for the rapidly developing companies, universities and government organizations have urban, educated working class really brings home the enormity utilized the Bay Area Council platform over the past ten years,” of it all. Our tour took us to three major industrial cities in the explains Del Christensen, Chief of Global Business Development southern part of China—Shanghai, Hangzhou and Nanjing—and for the BAC. each city had the hum and buzz of people on the move. Participating in this year’s BAC Life Science Delegation were We met with municipal party officials, university professors myself and and administrators, investors, entrepreneurs, incubators and • Dr. Jay Keasling, CEO of Joint BioEnergy Institute (JBEI) companies. Each location, each meeting, each person seemed and Demetrix, Professor at UC Berkeley well aware of the strength and scope of the California life science • Dr. Omri Drory, Head of Corporate Development, industry and presented an enthusiastic and optimistic invitation Twist Bioscience to collaborate. Some expressed interest in forging partnerships with California cities and regions to bring outsourced research, • Dr. Geoff Nosrati, Chief of Staff, Aduro Biotech

Biocom LifeLines Fall 2017 21 BAY AREA CONT.

testing, or clinical trials and manufacturing resources from their a little less steep. We encourage Biocom members who are hometown companies to advance certain innovative technologies. interested in exploring partnerships in China to connect with Others detailed their desire to build or acquire life science us as we continue to explore how and where we can assist with incubators and startups in the Bay Area. Several prospective seizing the opportunities that exist between our two countries. investors were keen to learn about Biocom’s Global Partnering Conference scheduled for February 28 – March 1, 2018. Others laid out the services that they can provide to US companies looking to set up shop in China. Dr. Drory of Twist Bioscience added, “China has the scale, know-how and ambition to be a world leader in many industries and have put life sciences as a priority. Life science, biotech Michelle Nemits is the Director of and synthetic biology is flourishing in China and it becomes a Business Development in the Bay Area. big market for Twist. We are looking for customers and partners in China to work with in unlocking this huge market.” In all, it seemed as though this region of China is eager to engage and ready to further grow this sector of their economy and having the BAC platform in place makes the learning curve

ChemDiv SM Cardiovascular CNS Infectious The chemistry of cures Inflammation Oncology Metabolics

EXPEDITE YOUR DRUG DISCOVERY

Integrated Drug Discovery & Development Services

1.6 Million Unique Compound Collection

Over 25 Years of Experience

More Than 2,500 Customers Worldwide

SEE FULL LIST OF OUR SERVICES www.chemdiv.com BIOCOM LA By Dina Lozofsky, Executive Director, Biocom LA

The Future’s So Bright For Life Sciences in LA, We Have to Wear Shades

2017 has been a great year for the advancement of our industry in “In a span of just a few short years, we grew from fewer than 10 Los Angeles. Some of the highlights of our progress: employees to almost 700. The company’s value increased 2300% • Local industry leaders had the opportunity to meet with LA from the time of our IPO to nearly $12 billion with the acquisition Mayor Eric Garcetti to discuss the needs of our industry and by Gilead Sciences.” how we can all work together to support growth in the region. While highly publicized, this deal is not the only one of note from • There were several important FDA approvals, including the LA region. According to the Q2 PwC/CB Insights Healthcare approval of the first drug in nearly 20 years for sickle cell, Moneytree Report (http://www.pwc.com/us/lifesciencesmoneytree), a quarterly report that covers US Venture Capital funding for an inherited disease in which abnormally shaped red blood healthcare related industries, the LA/OC region was third in the cells can’t properly carry oxygen throughout the body, which nation in the first two quarters of 2017 in the number of funding can cause severe pain and organ damage. The drug was deals and the total value of the deals in our industry. (note that developed at Emmaus Medical Inc., a spin out from Biocom Q3 data was not yet available at the time of writing this article). In member LA Biomed. Q1 of 2017, LA/Orange County funding was up 220% to $ 246M • We launched a new entrepreneur bootcamp with Biocom compared with funding for this sector in Q4 of 2016, with the member Cal State Los Angeles and other regional partners. number of deals also up by 160% from the prior quarter. See the The LA Biostart program is federally funded by an i6 graph of Q2 data below. Challenge grant. • Los Angeles to host 2028 Olympics (I had to throw that one in!)

ChemDiv But, most important of all, we’ve seen SM Cardiovascular CNS Infectious Inflammation Oncology Metabolics an uptick in funding for our industry in The chemistry of cures this region and a landmark acquisition D of LA-based Kite Pharma, Inc. by Gilead EXPEDITE YOUR DRUG DISCOVERY Sciences, Inc. On August 28th, Gilead and Kite announced that Gilead would be acquiring the LA-based industry leader D in the emerging field of cell therapy, Integrated Drug Discovery & Development Services which uses a patient’s own immune cells to fight cancer. This was the first major 4 1.6 Million Unique Compound Collection acquisition in our region by a US big D 4 pharma company and the largest ever pre- 4 commercial biopharma acquisition. Can Over 25 Years of Experience Kite do for Los Angeles what Hybritech did for San Diego? That remains to be D

More Than 2,500 Customers Worldwide seen, but Kite’s journey in Los Angeles is a great example of what can be done here—from the roots of the founders and science at UCLA to IPO to acquisition by D Gilead. As Dr. Belledegrun said in a thank you note to his supporters: SEE FULL LIST OF OUR SERVICES www.chemdiv.com

Biocom LifeLines Fall 2017 23 LOS ANGELES CONT.

Some exciting examples of 2017 deals: • Science 37, which is helping streamline the world of clinical trials by making them more convenient for • Biocom member Ritter Pharma, a leading developer of participants, closed a $29 million Series C to fuel the novel therapeutic products that modulate the human gut company’s expansion. microbiome, announced the closing of its public offering of approximately $23 million. They are working on a drug has • Biocom member IndiMolecular, Inc., a developer of protein the potential to become the first FDA approved treatment for catalyzed capture agent (PCC) biotechnology for research lactose intolerance. tools, diagnostic agents, and PET imaging, raised $11.5M in June in a Series A funding that was led by M Ventures • Biocom member Immix Biopharma Inc., announced the close (Merck Ventures BV, a subsidiary of Merck KGaA). of their Series A on August 28th. The funds will be used to complete a phase 1b clinical trial for their lead candidate, I can’t wait to see what the future holds for this industry in 2018, Imx-110. but the LA area is clearly gaining momentum and more of the • SetPoint Medical, a biomedical technology company recognition we need to attract capital to our region. developing a bioelectronic therapy for chronic inflammatory diseases, secured $30 million in Series D equity financing. • Sienna Biopharmaceuticals received $40 million in financing AND launched an IPO in 2017. They are a clinical-stage biopharmaceutical company focused on innovations in medical dermatology and aesthetics. • Biocom member ImaginAb, who is developing an imaging agent Dina Lozofsky is the Executive Director of for imaging changes in cell tumors, recently raised $8M. the Biocom Los Angeles office.

• +50 years industry experience developing assay kits and reagents for drug discovery • +50 years industry experience developing assay kits and reagents for drug discovery • Custom assay development: biochemical, cell-based and biomarkers • Custom assay development: biochemical, cell-based and biomarkers • Conversion of ELISA to no-wash assays: TR-FRET, AlphaScreen/AlphaLISA • Conversion of ELISA to no-wash assays: TR-FRET, AlphaScreen/AlphaLISA • Critical reagent generation: TR-FRET fluorophore labeling, AlphaScreen/AlphaLISA bead conjugation • Critical reagent generation: TR-FRET fluorophore labeling, AlphaScreen/AlphaLISA bead conjugation • Best antibody pair identification for TR-FRET and AlphaScreen/AlphaLISA immunoassays • Best antibody pair identification for TR-FRET and AlphaScreen/AlphaLISA immunoassays • Shortest turnaround time on the market. Extremely competitive pricing • Shortest turnaround time on the market. Extremely competitive pricing

619-330-9600 ext.101 6i1n9fo-3@3b0i-o9a6u0x0il i uemxt..c1o0m1 [email protected] www.bioauxilium.com BIOCOM INSTITUTE By Liisa Bozinovic, Executive Director, Biocom Institute

1,000-Times Stronger: Our Commitment to Workforce Development

My work life started at the age of 10 with a neighborhood paper A study by McKinsey & Company, Education to Employment: route. I was responsible for the daily delivery of 80 papers. Next Designing a System that Works, raised the question: how came a job as a camp counselor, and then as a summer lifeguard. can a community move its young people from education to Finally, I applied for my first summer college internship. I employment? Students are graduating with the financial burden bombed my panel interview and didn’t get the job. When I finally of student loans and yet can’t find a job. Employers have open got accepted into an internship program at General Motors it positions that can’t be filled because they can’t find candidates was an eye-opening experience. I was the front-line supervisor with the right skills. Fewer than half of students and employers on the second shift in a steering component factory. I can’t believe that new graduates are adequately prepared for entry- say that I overly enjoyed the experience, but I learned more in level positions. one summer about communication, negotiation, motivation and Our education partners can’t do it alone. Companies must supervision than I did from everything I’d done to that point. be more closely connected to the academic institutions and The next two summers spent as a General Motors intern were students, and that’s where Biocom Institute can help. While invaluable experiences on many fronts, not the least of which we have our “go to” partners that always come through when a was that I realized I did not want to be a frontline supervisor in school group wants to take a tour of a biotech company, or one of a union-based manufacturing plant or go into marketing. our veterans needs a mentor, or a teacher makes a request for a Perhaps it was that first internship that got me hooked on STEM professional in the classroom, we need more. We need you. workforce development; I sure recognized the need to treat To industry members: this is a call to join us. 2018 will bring my education like a job, find internships, hone my soft skills, new campaigns to engage with workforce initiatives. We will embrace career development and more. I thought it was all work for you and with you. There are a variety of programs and about getting the right training. But I was wrong. It’s not about services where you can participate and contribute. We promise internships and instruction. It’s so much more. I agree with it will be rewarding and fun. And it will serve your needs, no former Labor Department Secretary Thomas Perez who said, matter the size of your company. “we can no longer afford to simply ‘train and pray’.” Together we’ll put the California life science industry on the Biocom Institute is excited to be rooted in workforce map as the industry and region with the most coordinated, development for the life science industry and continuing to comprehensive and effective workforce development initiatives support programs that can help people far beyond simple training. around. You can start by reaching out to us. Let us know who • +50 years industry experience developing assay kits and reagents for drug discovery 2018 marks our 10-year anniversary and I’m more excited your best contact is within your company to connect with on this than ever because it dovetails with achieving 1,000-member effort. Get in touch directly: [email protected]. I’d love to status for Biocom. The Biocom Institute can point to plenty hear from you. • Custom assay development: biochemical, cell-based and biomarkers of accomplishments over the past decade, such as training and retraining hundreds of individuals for various careers in • Conversion of ELISA to no-wash assays: TR-FRET, AlphaScreen/AlphaLISA the life science industry, providing unique and engaging STEM experiences to tens of thousands of San Diego’s kids every year, hosting an annual data analytic hackathon ( with 220% YOY • Critical reagent generation: TR-FRET fluorophore labeling, AlphaScreen/AlphaLISA bead conjugation increase in student participation) and, working to inform and Liisa Bozinovic is the Executive Director assist hundreds of military veterans considering a transition of the Biocom Institute. • Best antibody pair identification for TR-FRET and AlphaScreen/AlphaLISA immunoassays to the life science industry. Mostly though, we are excited at the scale and scope of Biocom’s membership and look forward • to engaging with ALL of Biocom’s California-based industry Shortest turnaround time on the market. Extremely competitive pricing member companies. We have seen and felt their unwavering commitment to workforce development.

619-330-9600 ext.101 [email protected] www.bioauxilium.com Biocom LifeLines Fall 2017 25 BIOCOM WEBSITE By Harry Chang, Digital Content Editor, Biocom

What’s New on the Completely Revamped Biocom Website

By now, you may have noticed our website, Biocom.org, has and Professional Development sections. Members can contact undergone a substantial makeover. Your eyes aren’t deceiving Biocom Institute year-round for corporate and individual give-back you—it has. We’ve completely revamped our site to give our and volunteer opportunities, and invest their own development with growing membership faster and easier access to the resources discounted member courses for life science professionals. they need, all while giving site visitors a cleaner, more modern, News resources are also easier than ever to access, with a Biocom mobile-first user experience, no matter what information they’re Newsroom featuring media resources, a brand new blog-style home looking for. for Biocom’s newsletter, the Biocommunique (BCQ), and sections for Those interested in our public policy initiatives can now Biocom news releases, Biocom in the News, and Biocom Viewpoints. easily track bills in our State and Federal Legislation of Interest Finally, the new Biocom.org employs a secure HTTPS-encrypted sections. Members can stay up to date on the latest life science browsing experience, a personalized Our Team page, 100% policies we’re lobbying for and against at the local, state, and original content and stunning graphics reflect on Biocom’s 20+ federal levels in the stunning new Policy Priorities section. In year commitment to the life science industry and commitment to the new Action Center, members can make their voices heard California’s life science future. year-round on the life science issues that matter most. We invite you to explore the new website at Biocom.org today for The new Biocom.org also features a simpler Events and an entirely new experience. Networking section. Once clicked, the events and networking tab sends visitors to our events calendar, where members can filter Biocom’s 150+ annual proprietary events by location, date, and topic, or choose to see additional events hosted by Biocom members and partners. It’s also easier to view Biocom’s committee offerings. Our dedicated Committees page gives you a top-down view of categories, and individual committee pages showcase committee missions, guidelines, responsibilities, and join contacts. In the new Capital Development section, highlights include the ability to submit funding and partnering inquiries year- round, view upcoming Partner and Venture Days around California, as well as information on participating companies, and gain invaluable information specific to life science startups in California. Members can also get savings news and information whenever they need it, all in one place, in the new Purchasing Group section. The new Savings Portfolio gives each of Biocom’s 30 vendors a place to post discounts and updates, and savings categories give members savings insights specific to Lab, HR/ Finance, Facilities/Operations, Data/Communications, and Travel. For members and corporate leaders looking to get involved in Harry Chang is the Digital Content Editor the community, Biocom Institute’s revamped section features for Biocom. dedicated STEM, Veterans, Workforce and Entrepreneurship,

26 Biocom LifeLines Fall 2017 CAPITAL DEVELOPMENT By Jennifer Landress Senior Vice President & COO, Biocom

The Key to Success? Relationship Building.

Everyone in business knows the power of networking connect with members and learn about what they are working and building relationships. It’s incredible how a simple on. In 2017 alone, we have held Partner Days with GSK DPAc, conversation over coffee can lead to an introduction to Vertex Pharmaceuticals, Illumina, Boehringer Ingelheim, and someone who will fund your company. The beauty of Eli Lilly. We have done Venture Days with Taiho Ventures, building an assortment of relationships is that you never Astellas Ventures, Takeda Ventures, SR-One, Longitude know when it will yield a significant connection. At Biocom, Capital, Illumina Ventures, Novo Ventures, and RiverVest. specifically within the Capital Development pillar, our goal These events have taken place in San Diego, in Los Angeles is to facilitate building these relationships between our and in the Bay area—and companies have participated in nearly 1,000 members and investors, large pharma, big these events from throughout the State of California. biotech and other individuals who can help accelerate a Through Biocom’s ability to unite the statewide ecosystem company’s success. These connections not only benefit we made 200 direct connections so far this year. That does our members but they benefit the California life science not include the countless connections and introductions when ecosystem at large. schedules don’t align. It is important As I build my own to focus on the relationship building relationships, it is through events like these, and although important to listen to what it is difficult to measure specific deals, is being said relative to IN 2017 ALONE, BIOCOM MADE the value of the introduction and the funding for companies. The 200 DIRECT CONNECTIONS conversation is priceless. life science ecosystem is In all of these events, Biocom creates evolving and the avenues THROUGH PARTNER DAYS the avenue for members to tell their that large pharmas in story and to build or nurture an existing particular are exploring AND VENTURE DAYS relationship. We will continue to calendar for filling their pipelines more of these opportunities. are changing. No longer To ensure that you are in the know, is the core focus on make sure to bookmark this webpage: internal research, pharmas are networking more broadly www.biocom.org/s/capital-development/. and evaluating technology earlier—looking at partnerships with academia and early stage companies and building relationships with venture funds. There is a growing Advice from the Experts demand to just know what is going on. Snippets of advice given throughout the year from various panels As I have talked with various representatives of large and presentations that Biocom has organized: pharma and venture funds, they all tell me the same thing: it is critical to the success of their business to know people • When pitching, you need to have a clear concept and vision and what they are working on so when something becomes with lots of data to back it up. Plus, good people and a solid relevant they can move on it. They want to/need to build hypothesis. a network of individuals that they can quickly get to the • The more that entrepreneurs are educated, the better armed technology. they are to go into discussions. At Biocom, and in particular with our Partner Days and • Ask questions before you begin your pitch and listen to the Venture Days programs, we aim to do just that. We broker response—this will help set the course for the conversation. opportunities for individuals in specific therapeutic areas to

Biocom LifeLines Fall 2017 27 • The most important introduction is the warm introduction to • Don’t be frustrated by a No—it may just mean No at the a funding partner who can help facilitate connections. moment. It’s good practice to stay in touch, keep an open • Be prepared to talk about your differentiation strategy. How dialogue and send new data as it becomes available. That No will your concept move the needle? could quickly become a Yes when the time is right. • Always a plus to have clinical data. • Have a well thought out strategy and be concise when telling it. • The goal is to get beyond the initial 30 minute meeting— you want to get whomever you are meeting with excited about the mechanism and you want to get an invitation to tell more about what you are doing. Remember, some of the individuals you are meeting see 2,000 ideas a year! You need to say something in 30 minutes that makes them want to talk to you again. In addition to general oversight of the organization, Jennifer spearheads • Do not spend time on the size of the market or outlining the Biocom’s international outreach, capital problem in specific area. development, and marketing efforts.

PROFESSIONAL SCIENCE MASTER’S IN BIOTECHNOLOGY

CALIFORNIA STATE UNIVERSITY SAN MARCOS

• Combines advanced coursework, laboratory training and real-world experience • Employs a cohort model ensuring small class sizes and guaranteed seats • Culminates in a capstone Semester-in-Residence project • Evening classes taught by industry experts to accommodate working professionals • Boasts a 97% employment rate for graduates

APPLICATIONS NOW OPEN FOR FALL 2018

FOR MORE INFORMATION OR TO REGISTER: 760-750-4004 I [email protected] WWW.CSUSM.EDU/EL/PSMLIFELINES

28 Biocom LifeLines Fall 2017 BIOCOM PURCHASING GROUP By Rick Fultz, Chief Business Development Officer, Biocom Managing Director, Biocom Purchasing Group

1,000 Members Means Millions More in Savings

A group purchasing organization (GPO), in its simplest form, is an those calls and facilitating routine advisory check ins with our entity that is created to leverage the purchasing power of a group of members as we chart a path for new contract areas. businesses to obtain favorable pricing, terms, and conditions from Wherever those conversations lead, we are confident the suppliers in exchange for access to a large potential opportunity. contracts that we will be able to negotiate over the next few years If done correctly, it is simple math; the better the opportunity for will continue to provide increasingly critical bottom-line savings for suppliers, the better the programs and savings for the customers. our members. Our team has been hard at work renegotiating on our members’ “What I love about the Biocom Purchasing Group contracts behalf with every new milestone: 600 members in 2014; 750 in are the unique terms and conditions negotiated,” says Wendy 2015; 850 in 2016; and now Hernandez, Director of today, on the doorstep of 1,000. Corporate Procurement for Each major milestone means NuVasive. “For us, the best more leverage, which means “WHAT I LOVE ABOUT THE BIOCOM pricing is only one side of better deals. Together, we grow PURCHASING GROUP CONTRACTS ARE the equation. We’re always stronger and prosper. looking for the best overall Our mantra of ‘member- THE UNIQUE TERMS AND CONDITIONS. ” cost of doing business, and focused, member-vetted, that means pairing effective - WENDY HERNANDEZ, member-driven’ has continued cost management with best- DIRECTOR OF CORPORATE PROCUREMENT, NUVASIVE to allow us to translate member in-class industry partners feedback into solutions and and exceptional service. positioned us as the strongest Biocom always delivers and GPO in this industry. Together with our members, this simple but is standing by to ensure we are happy with the endorsed supplier.” powerful equation of leverage and member participation translates Just as people are often recognized as the most important asset into critical operational excellence for everyone. of a company, our members are ours. We’ve had the privilege of June Lombardi, Senior Director of Procurement for the Scripps serving some of our members since the beginning in 1995; many Research Institute, agrees, “Biocom Purchasing Group’s ability more for over 15 years, and many new ones who are just starting to to leverage the purchasing power of their large member base has experience the incredible goals we can accomplish together. unlocked a level of competitive pricing impressive even for an The best businesses are agile, flexible, and adaptable. They institute of my size, and is a GPO we can trust to negotiate with are always on the lookout for best practices and embrace our best interests in mind.” continuous improvement. Luckily for us, we’re surrounded by Representing almost 1,000 members, we can negotiate on luminaries on a daily basis. We’re proud to have the opportunity behalf of hundreds of millions of dollars of spend, resulting in to raise the bar together, and we’re looking forward to unlocking contracts so competitive they are now utilized by even our biggest the next level of potential at our one thousand member members. It’s a testament of just how impactful the deals have milestone heading into 2018. become. Our Thermo Fisher Scientific contract alone has almost 400 members enrolled. While this is great news for Thermo Fisher Scientific, it is also creating another positive effect in the marketplace. The feverish pace at which new suppliers are calling to be part Rick Fultz is Chief Business Development of the savings portfolio has accelerated rapidly in direct response Officer of Biocom and Managing Director to our recent growth. Our contracts team is hard at work fielding of the Biocom Purchasing Group.

Biocom LifeLines Fall 2017 29 GUEST By Yi Yang, Tax Director, CBIZ and MHM

Get a Jump Start on Tax Reform

The road to tax reform is proving difficult, which complicates What Businesses Can Do Now business and individual tax planning. Many may have approached Businesses can prepare for the possibility of a future lower corpo- 2017 in expectation that next year might be more tax-friendly. In rate tax by looking at strategies to defer income and accelerate reality, the details on when, how and what reforms will be passed deductions for 2017. Accelerating purchases to take advantage of are murky. Fortunately, there are steps to take now to anticipate the Section 179 expensing election and bonus depreciation may and prepare for future changes. It starts with understanding what be another option to consider. Manufacturers currently using the types of tax reforms may be coming. Section 199 deduction may want to ensure they are claiming the maximum deduction for the 2017 year. What We Know of the Tax Reform Plans Multinational organizations should consider undertaking an The “Big Six”—House Speaker Paul Ryan, Senate Majority earnings and profit (E&P) study. An E&P study can help determine Leader Mitch McConnell, Finance Chairman Orrin Hatch, National the amount that would be subject to repatriation. Steps may be Economic Director Gary Cohn and Treasury Secretary Steven taken now to reduce the E&P that would be taxed under tax reform. Mnuchin released an outline of their tax reform plan on September 27. The Unified Framework for Fixing Our Broken Tax Code What You Can Do to Prepare for Individual Tax Changes (Unified Framework) contains many of the provisions of previous Similarly, individuals can prepare for the possibility that lower indi- tax reform proposals, including the House Republican Blueprint, vidual tax rates may be coming. Individuals may want to defer and the Trump Administration’s plan. income and accelerate deductions for 2017. Consider maximiz- It collapses individual tax brackets into three groups, nearly ing deductible expenses such as charitable donations and state doubles the standard personal tax deduction, and eliminates the and local income and property taxes while keeping an eye on AMT Alternative Minimum Tax (AMT). The Unified Framework also considerations. enhances the child tax credit. Itemized deductions, other than If possible, individuals should delay making gifts that would trig- charitable contributions and mortgage interest, are repealed, as ger transfer taxes. They should also evaluate the impact on their are estate taxes and the generation-skipping transfer tax. In the estate plans of a potential loss of stepped-up basis due to repeal framework, the corporate tax rate is lowered to 20 percent. Pass- of the estate tax. The loss of the deduction for interest expense through entities will be subject to a top rate of 25 percent, with may also affect estate planning, and individuals should consider a reference that the final tax reform would include measures to the use of debt in the estate if the deduction is no longer available. prevent the recharacterization of personal income into business income for high income earners looking to reduce their top tax rate. Stay Tuned Trump had previously proposed a 15 percent rate for both corpora- Many questions remain about the Unified Framework, chief among tions and pass-through entities. them how the proposed tax cuts would be financed. The lingering Businesses would be able to immediately expense capital invest- uncertainties may mean the reforms outlined will not affect 2017. ments made after Sept. 27, 2017, for five years. What would happen Businesses and individuals can still be prepared by considering to other business tax provisions is less clear. The framework specifi- existing opportunities to reduce their tax burden for 2017. A tax cally eliminates the Section 199 domestic manufacturing deduction. advisor can help navigate the uncertainty and optimize business It preserves the research and development (R&D) tax credit and and individual tax plans. incentives for low-income housing. The C corporation deduction for interest expense would be limited, and whether it would be available for pass-through entities would be weighed by future committees. Dividends from foreign subsidiaries would receive a 100 percent exemption. Foreign earnings that have accumulated overseas would be deemed repatriated. The tax rate for repatriated earnings was not Yi Yang is a Tax Director in the San Diego identified, but the Unified Framework specifies that illiquid assets office of CBIZ and MHM. She specializes would be subject to a lower rate than cash assets. in corporate tax provisions.

30 Biocom LifeLines Fall 2017 BIOCOM INSTITUTE By Sara Pagano, Managing Director, Biocom Institute Festival of Science & Engineering

STEM In The Community - 10 Years in the Making

As we travel the road to 1,000 members, the horizon is full of is a hotbed for innovation, offering a unique collaborative spirit, opportunities for STEM. It’s a rich road, full of twists, turns, a high concentration of world-class research institutions, and a thrilling curves, and seat-belt-tightening moments of exhilara- strong foundation to create and build new companies. Today, as tion. A quick look in the rear view mirror gives us a glimpse of we lead the San Diego Festival of Science & Engineering, we will what has flown past, and a glance forward leads us onward to the continue to be a catalyst and collaborator, showing students and next destination for STEM in our community. parents how science, technology, engineering and math translate In 2008, Biocom’s roster was close to 500 members. That to promising careers and fuel our economy. Also, we keep an eye same year, the Biocom Institute was incorporated as a 501(c)3. on the road ahead: stay tuned for new STEM outreach programs The mission? To build a better workforce for the life science in our other life science clusters across the state in 2018. industry. Meanwhile, the Biocom Institute got connected with Local leader Larry Bock is a hero to those of us in STEM, here something called “The San Diego Science Festival.” Little did in San Diego; we are proud of his vision. We are also proud of we know that this 2008 festival would be labeled the “largest our community’s success in being awarded seed funding from the multicultural, multigenerational, multidisciplinary celebration of National Science Foundation. We are grateful to many others— science ever seen on the West Coast,” with Biocom Institute in especially to our early pioneering partners at UCSD. the leadership role. We have listened to the community and grown with the In its inaugural year, the Science Festival was a collection of times: our major STEM initiatives now occur across one week, 500 events held across San Diego County. It lasted a month and and our signature event is now called the Festival of Science & culminated with the first-ever EXPO Day on April 4, 2009 in Engineering. We now claim more than 70,000 participants. We Balboa Park. A record-breaking crowd of 50,000 people attended. are proud to be the primary K−12 STEM initiative of the Biocom Well, along with the crowds came traffic (sometimes the road to Institute and are thankful that the Biocom leadership understood 1,000 needs some Cal-Trans road-widening). According to one the significance of keeping this Festival moving forward for San media statement, “the backup of cars on Interstate 5 waiting to Diego and its families. exit for Balboa Park stretched five miles.” Event planners quickly Though we will always have the honor to say we were one of the made the fix the following year by moving EXPO Day to Petco country’s first(s), there are now more than 50 science festivals Park, with plenty of public transportation routes and lots of park- taking place throughout the United States, from rural areas to ing. More importantly, the traffic jam reflected the tremendous major cities. Join us March 3−11, 2018 to help honor the past, demand for public science events, revealing a craving among celebrate the present and strengthen the future for the next 10 students, teachers, and parents for high-quality STEM experi- years of the San Diego Festival of Science & Engineering! Visit us ences and exposure. at www.lovestemsd.org. In the following years, we traveled the road and our journey became a collective movement to integrate science into every- one’s day-to-day culture. A movement that has put a little sexy into the word “STEM”, and transformed the definitions of “nerd” and “geek” from stereotypes to smart and strong. As we’ve accel- erated our efforts, we’ve made this industry and its career paths accessible to men and women of all races and socio-economic Sara Pagano is the Managing Director backgrounds. of the Biocom Institute Festival of Science So how do we keep moving forward and remain a leader in this & Engineering. movement? First, we continue to cultivate conversations that bring recognition to how science changes lives every day. Second, we recognize and capitalize on the fact that geographically, science (and advancement) is truly right here in our own backyards. San Diego

Biocom LifeLines Fall 2017 31 EVENTS By Shaye Exner, Senior Director of Conferences and Corporate Sponsorship, Biocom

It Takes More Than Home Runs to Succeed

Baseball Hall of Famer and local San Diego legend Tony Gwynn said, The topics were broad, and if you were in the life science commu- “The minute you’re satisfied with where you are, you aren’t there nity, you simply had to be there. Back then, Biocom organized just anymore.” During my 15-year tenure at Biocom, Tony’s words rang one annual conference each year, CALBIO. This was an opportu- true: when I look back at where Biocom was 15 years ago and then nity to stay abreast of the advancements in the biotech industry in to where it is today, soaring to 1,000 members, I ponder the gifted San Diego. We also held quarterly executive receptions. Bringing right-fielder’s philosophy. As a veteran of the Biocom Events team our leaders together to connect has always been a primary focus. I have seen our organization achieve growth and greatness—always Everyone knew each other, everyone supported each other. It was “a with a team approach, and always with a laser-focus on our members. small world” back then. Just as it takes singles, doubles, triples, and home runs to have Fast forward 15 years and we have seen our membership grow not a winning season, it takes small, medium, large, and global events just in numbers but also in diversity and geography. 1,000 members to achieve success for our life science industry. At Biocom, we had came to us for the promise that only Biocom can provide: we swing for 6 employees when I started. And while we mostly hit regular singles the fences on behalf of our members. Biocom’s growth has changed and doubles, that led to well-timed triples and keen-eyed home our strategy completely when it comes to developing programs for runs. Today, we are a state-wide staff of 48, with a 60-person board, our members. Gone are the days of “one-size-fits-all” events. As a and offices around the world, making Biocom the largest life science statewide organization representing all segments of life science, we trade association in the United States by membership and staff. are now organizing specialized events that target the diverse compa- It took time, experience, skill, dedication, wisdom, and a deeply nies that make up our membership. Precision medicine, big data, committed team of industry veterans with decades of experience to genomics, digital health, combination products, AI, cybersecurity, achieve this milestone. chemistry outsourcing, workforce development, and capital develop- In my first year at Biocom, I could recite all of our members by ment are just a few of the areas where Biocom provides customized name. If someone asked if company Y was a member, I would know events. Furthermore, we are a traveling team: our events are now immediately. I would know at least 1 or 2 people from that company up and down the coast, across the country and across oceans. We to introduce you to. I would know what therapeutic area that company also target industry leadership with programs for CEOs, CFOs, CIOs, was working in and what round of financing they were in. I knew all HR heads, and Business Development professionals. We no longer this because the year was 2002 and we only had about 200 members. connect the mighty few in our backyard. Our events now link across I get asked all the time, how is it being at the same job for 15 time zones and create collaborations around the world. 10 events per years? Don’t you get bored? Don’t you want to try something new? And year and one regional conference became 150+ events a year and five what I can honestly say is that 2017 has been the best year of my major conferences, including our flagship Annual Global Partnering professional career. The growth of this organization to almost 1,000 Conference. Six well-known employees have become 48 valued members has created an environment that fosters collaboration, inge- colleagues. 200 members have become 1000. Bored? I promise you nuity, motivation, creativity and most important to me, excitement. I’m not. The great thing about change is that it keeps you flexible, Let me explain why… fluid and open to new ideas. Change makes you smarter. Every time Events are the cornerstone of most trade associations. They aim to you are forced to adapt, you learn new skills. Change forces you out provide their members with networking, education, idea-sharing, and of your comfort zone and into new experiences. I am more energized access to best practices and brightest minds. Events provide a forum and passionate about my job 15 years later than I ever expected. for members to exchange ideas and develop new ways to accelerate In the immortal words of Miley Cyrus, “Change is a thing you can life science industry success. I have seen more experienced members count on. I feel so much younger now.” help newer ones; I have watched new partnerships form, I have seen deals get done, and I have watched milestones reached and products approved. I have cheered hundreds of industry home runs. For those of you who can remember back, Biocom once held not-to-be-missed monthly breakfast meetings. These events were Shaye Exner is Senior Director of recognized as the “meet ups” for the biotech industry in San Diego. Conferences and Corporate Sponsorship for Biocom.

32 Biocom LifeLines Fall 2017 MEMBERS IN ACTION

BIOCOM PAC ANNUAL ELECTED OFFICIALS RECEPTION

Illumina’s picturesque i3 campus provided a beautiful setting for this year’s Biocom PAC Elected Officials Reception. Biocom members had the opportunity to chat with policy makers in a warm, relaxed setting and educate them about the industry and the advances being made. Our special thanks to Signature Sponsor Genentech and Host Sponsor Illumina for making the incredibly successful event possible.

Biocom LifeLines Fall 2017 33 MEMBERS IN ACTION

BIOCOM’S OPEN HOUSE + SUPPLIER SHOWCASE: On July 20th Biocom hosted over 600 members at Brian Malarkey’s Farmer & the Seahorse for the Annual Biocom Open House + Supplier Showcase and an unforgettable evening on the Torrey Pines mesa. The energy in the crowd was magnetic as members navigated through the Game of Life (Science), visiting with suppliers in uniquely crafted on-site activations, experiencing food & drink pairings from regions in California, unlocking prizes and soaking in the sweet sounds of summer from Biocom member band, Chicken Wire, and local artist Mike Mydral and his Trio.

34 Biocom LifeLines Fall 2017 Bench is commited to finding the “un-findable” Bench is commited to finding the “un-findable” and getting the “un-gettable” leaders. and getting the “un-gettable” leaders.

benchinternational.com benchinternational.com 36 Biocom LifeLines Fall 2017 MEMBERS IN ACTION

BIOCOM DEVICEFEST & DIGITAL HEALTH SUMMIT: Biocom held the 10th annual DeviceFest this year with a digital health focus. The event delivered on its promise to provide thought provoking panel discussions and case studies on reimbursement, behavior modification, funding strategies, and a pulse of the industry from EY. The audience participated in voting for this year’s Five in 5 in the Hotseat winner and crowned Braykion the hottest device company in California.

Biocom LifeLines Fall 2017 37 BOARD OF DIRECTORS

BOARD OFFICERS AND EXECUTIVE COMMITTEE: James Mackay, Ph.D, Ardea Biosciences CHAIR: Daniel Burgess* Damien McDevitt, Ph.D., GlaxoSmithKline VICE CHAIR: Carin Canale-Theakston, Canale Communications* Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* CHAIR ELECT: Genomatica, Inc.* Christophe Schilling, Ph.D., Tracy Murphy, Kilroy Realty* VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, J.D., Ph.D., DLA Piper* Steven Pacelli, Dexcom VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* Kenneth Polin, Jones Day VICE PRESIDENT – INDUSTRY: Richard Pascoe, Apricus Biosciences* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* Trindl Reeves, Barney & Barney LLC* CHAIR EMERITUS: Theodore Schroeder, Zavante Therapeutics* Dan Ryan, Alexandria Real Estate Equities PRESIDENT & CEO: Joe Panetta, Biocom* Dean Samsvick, KPMG Steven Bartz, Ph.D., Merck & Company James Schaeffer, Ph.D., Calibr* Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Timothy Scott, TEGA Therapeutics* Sandra Brown, Ph.D., University of California, San Diego Mark Stevenson, Thermo Fisher Scientific* Terrance J. Bruggeman, Avenzoar Pharmaceuticals, Inc. Lesley Stolz, Ph.D., JLabs California Bruno Buisson, Ph.D., Neuroservice Tsuneo Takahashi, NF Corporation Ho Cho, Ph.D., Celgene Kevin Tremblay, BioMed Realty Trust Carol Cox, NuVasive David Weitz, Takeda California Charles Dadswell, Illumina* Kenneth Weixel, Deloitte & Touche, LLP John M. Dunn, Vital Therapies Stephen Welter, San Diego State University David Enloe, Althea CMO Tom West, Hologic Kelly Farrell, Pfizer La Jolla Matthew Williams, AbbVie Stephen Ferruolo, J.D., Ph.D., USD School of Law* Scott N. Wolfe, Latham & Watkins Oliver Fetzer, Ph.D., Synthetic Genomics LIFE DIRECTOR: M. Wainwright Fishburn, Jr., Cooley LLP* Kennon W. Baldwin, Ferguson Pape Baldwin Architects* Jack Florio, Objective Capital Partners David Hale, Hale BioPharma Ventures* Gregory Fond, Sanofi Brent D. Jacobs, Cushman & Wakefield* Gregory Frost, F1 Oncology Magda Marquet, Ph.D., Althea* Carol Gallagher Tina Nova, Ph.D., Molecular Stethoscope Wolfgang Glaesner, Ph.D., Eli Lilly & Company Larry Stambaugh, Molecular Assemblies* Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Biocom Board Members-Ex-Officio: Ronnie Hanecak, Ph.D., University of California, Irvine Mark Cafferty, San Diego Regional Economic Development Corporation Richard Heyman, Ph.D., Metacrine Peter Callstrom, San Diego Workforce Partnership Guy J. Iannuzzi, Mentus Sunita Cooke, Ph.D., Mira Costa College Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation Scott Lippman, MD, Moores Cancer Center, UCSD David Kabakoff, Ph.D., Sofinnova Ventures Greg McKee, CONNECT Katherine Kantardjieff, Ph.D., California State University San Marcos Peter Preuss Steve A. Kay, Ph.D., University of Southern California Jerry Sanders, San Diego Regional Chamber of Commerce Paul Laikind, Ph.D., ViaCyte David Webb, Ph.D., Scripps Research Institute James Levine, Sapphire Energy* Jack Lief, BioRegenerative Sciences, Inc.* *Executive Committee Member COMMITTEE LEADERSHIP

Biocom Institute Board Committee* Regulatory Affairs Committee Public Policy Oversight Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. David Enloe, Althea CMO Larry Stambaugh, Molecular Assemblies Paul Laikind, ViaCyte Capital Development Committee* Intellectual Property and Patent Law Committee Carin Canale-Theakston, Canale Communications Daniel Hart, Knobbe Martens Olson & Bear LLP Purchasing Board Committee* David Kabakoff, Ph.D., Sofinnova Ventures Michael Mueller, Conatus Pharmaceuticals Jack Lief, CeleCor Therapeutics

CRO Committee Legislative Committee REGULATORY AFFAIRS COMMITTEE Richard Lin, Explora BioLabs Richard Ledford David Enloe, Althea April Grant, Alkermes Scott Cunningham, Covington & Burling LLP Digital Health Committee Apurv Kamath, Dexcom Medical Device Committee Veterans Committee Tony Grover, Banyan Biomarkers Josh Vosovic, Accenture Accelerated RD Environmental, Health and Safety Committee Mike Oliver, Spectra Science Cliff Hanna *Board Level Committees Dan Shiel, Pfizer La Jolla Oncology Committee Miguel de los Rios, RIFT Biotherapeutics Facilities Committee Bindu Gaddipati, Elixsys Andy Darragh, Ferguson Pape Baldwin Architects Eric Kowack, Ignyta Brent D. Jacobs, Cushman & Wakefield

COMMITTEE CORNER

Biocom’s 15 committees provide valuable networking, the chance to plan future Biocom events, and a forum to discuss critical issues within the industry. We are excited to announce the launch of committees in Los Angeles and the Bay Area for even more opportunities for our members to get involved with Biocom and the life science community. In this LifeLines, we are featuring the Facilities Committee and we hope to spark your interest in joining a committee where you can share your skills, knowledge, and expertise.

CRO COMMITTEE This committee was formed to build a unique support network between industry companies and CRO’s. The committee is comprised of representatives that have expertise in discovery, development, manufacturing, clinical research and/or marketing of therapeutic, device and diagnostic products. Committee members help to identify ways that industry members can work with CRO’s to strategize about their specific needs.

Interested in joining? Contact Kira Jenkins at [email protected]

Biocom LifeLines Fall 2017 39 PREMIUM MEMBER SPOTLIGHTS

www.patheon.com www.businesswire.com

Name: Zane Hirtzel Name: Steve Li Job title: Senior Account Executive Job title: Business Development Executive

Favorite movie: Heat Favorite movie: Inception Favorite book: The Lord of the Rings Favorite book: The Tipping Point, by Malcolm Gladwell Favorite quote: “Luck is what happens when preparation Favorite quote: “Don’t take life too seriously, you’ll never get meets opportunity.” out of it alive.” – Elbert Hubbard Favorite TV show: Breaking Bad Favorite TV show: Big Bang Theory Favorite restaurant or meal: Thai Favorite restaurant or meal: Mastro’s Steakhouse Favorite city: Auckland, NZ Favorite city: Rome Favorite actor/actress: Al Pacino Favorite actor/actress: Denzel Washington Favorite thing to do on the weekends: Hangout with my kids and friends Favorite thing to do on the weekends: Going to the beach in the summer and What CD can we find in your car: Tool snowboarding in the winter. Favorite hobby: Fitness What CD can we find in your car: I don’t play CDs in the car. I play Pandora stations. Favorite website: www.nzherald.co.nz Favorite hobby: Playing sports Favorite spot in Southern California: Corona Del Mar Favorite website: Google First job: Cashier Favorite spot in Southern California: Laguna Beach Favorite part of your job: Helping clients First job: McDonald’s If you could have another career, what would it be: A stock trader Favorite part of your job: Going to different parts of the world. Why did you start working in your industry: Interested in news and public relations. If you could have another career, what would it be: Veterinarian Why did you start working in your industry: Loved helping to make people feel better.

FEBRUARY 28st st The Lodge and MARCH 1 , 2018 at Torrey Pines

40 Biocom LifeLines Fall 2017 PREMIUM MEMBER SPOTLIGHTS

www.willistowerswatson.com www.troygould.com

Name: Alan B. Spatz Name: Debra Prol Job title: Managing Director Job title: Life Science Specialist, Client Advocate (Property & Casualty) Favorite movie: Its Complicated Favorite book: Great Gatsby Favorite movie: Good Will Hunting Favorite TV show: Homeland Favorite book: The Da Vinci Code Favorite restaurant or meal: Cassoulet Favorite quote: “When you talk, you are only repeating Favorite city: Los Angeles what you already know. But if you listen, you may learn something new.” – Dalai Lama Favorite actor/actress: Steve McQueen Favorite TV show: Modern Family Favorite thing to do on the weekends: Find something new to do in Los Angeles Favorite restaurant or meal: Merriman’s What CD can we find in your car: Dreamer by Eliane Elias Favorite city: Boston Favorite hobby: Art history Favorite actor/actress: Leonardo DiCaprio / Sandra Bullock Favorite website: Ebay Favorite thing to do on the weekends: Walk on the beach with my family. Favorite spot in Southern California: Los Angeles What CD can we find in your car: Fisher Price Sing-Along Classics, but if I had a CD of First job: Putt Putt Golf, Cincinnati Ohio mine in the car it would probably be Jack Johnson. Favorite part of your job: Creatively overcoming deal and negotiating obstacles to help Favorite hobby: Paddle boarding clients achieve their transaction goals. Favorite website: Biocom (of course) If you could have another career, what would it be: Hosting California’s Gold Favorite spot in Southern California: La Jolla Why did you start working in your industry: Wanted to be involved in many different types First job: Lifeguard / Swim instructor of businesses. Favorite part of your job: Helping my clients solve problems, and watching them bring lifesaving products to market. If you could have another career, what would it be: Travel blogger Why did you start working in your industry: I had an opportunity to join AIG’s underwriting training program. It was a great learning opportunity, and lead me to find a specialty that I was passionate about.

PREMIUM MEMBERS AbbVie Cooley LLP Kilroy Realty Patheon Airgas Cultura KPBS Perkins Coie* Alexandria Real Estate Equities Deloitte KPMG Pfizer Althea DestinHaus Latham & Watkins Prometheus Laboratories Bayer DLA Piper Marsh & McLennan Agency Thermo Fisher Scientific Biogen Eli Lilly Mentus TroyGould PC* BioLabs San Diego Ernst & Young Merck Research Laboratories VWR International Biomed Realty Trust Ferring Research Institute Mintz, Levin, Cohn, Ferris, Willis Towers Watson* Bridge Bank Fisher Scientific Glovsky and Popeo Wilson Sonsini Goodrich & Rosati Business Wire* Hologic Nixon Peabody YourEncore* Canale Communications Illumina Novo Nordisk Celgene Ivantis* NuVasive Cidara Therapeutics Johnson & Johnson Innovation, Office Depot COI Pharmaceuticals JLABS Panasonic Healthcare Conatus Pharmaceuticals Jones Day Corporation* * New Members from May 2017 to October 2017

Biocom LifeLines Fall 2017 41 BIOCOM MEMBERSHIP

Applied StemCell* Cellular Research Genelux Corporation PREMIUM Apricus Biosciences Center for Aquaculture Technologies Genentech Aquinox Pharmaceuticals Ceutix Labs* Genlantis AbbVie VWR International Aratome Channel Medsystems Genoa Pharmaceuticals Airgas Arcturus Therapeutics Chubu Technology Licensing Office Genomatica Alexandria Real Estate Equities Willis Towers Watson* Wilson Sonsini Goodrich & Rosati Arcus Bioscience Chugai Pharma USA* Genovo Corporation Althea Ardea Biosciences Cibus GenSignia Life Sciences YourEncore* Bayer Aries Pharmaceuticals Circle Pharma* Geron Corporation* Biogen Armetheon Circuit Therapeutics GlaxoSmithKline BioLabs San Diego Arrayomics Coherus Biosciences Global Biotherapeutics Biomed Realty Trust BIOTECH Arytha Biosciences Contract Biotics GlyTech Bridge Bank Asahi Kasei Pharma Coyote Bioscience USA Greenwich Biosciences AskGene Pharma* Crinetics Pharmaceuticals GWR Instruments Business Wire* 23andMe* Assembly Biosciences* CureMatch Halozyme Therapeutics Canale Communications 3E Therapeutics Corporation Aspyrian Therapeutics Curtana Pharmaceuticals Harpoon Therapeutics Celgene 3-V Biosciences Astellas Pharma CytoVale Helix 10X Genomics Cidara Therapeutics Atara Biotherapeutics CV Sciences Heron Therapeutics Abbomax COI Pharmaceuticals Atila BioSystem CytomX Therapeutics Histogen Abbott Laboratories Conatus Pharmaceuticals aTyr Pharma Dare Bioscience Horizon Pharma USA AbCyte Therapeutics Cooley LLP Audentes Therapeutics Dart Neuroscience Human Longevity Abide Therapeutics Deloitte August Therapeutics Decoy Biosystems Huya Bioscience International Abilita Bio DestinHaus Aukera* DEL Biopharma Ideaya Biosciences Abreos Biosciences DLA Piper Avanir Pharmaceuticals* Demetrix* IGM Biosciences* AB Systems* Avantgen Dermata Therapeutics Ignite Immunotherapy Eli Lilly Abwiz Bio Avelas Diagnostics for the Real World* Immix Biopharma Ernst & Young ACADIA Pharmaceuticals Avenzoar Pharmaceuticals DICE Molecules SV, LLC* Immunity and Me* Ferring Research Institute Access Biologics* Avexegen Therapeutics DiscoverX Corporation* ImaginAb Fisher Scientific Acea Biosciences Avidity Biosciences DNA Link USA Inception Sciences Genoptix Actavalon Aviva Biosciences DNAtrix Indee* ActivX Biosciences Hologic Bachem Americas DoDo OmniData IndieBio AcuraStem* Illumina Balance Therapeutics Dovetail Genomics Indi Molecular Adigica Health Ivantis BASF EA Pharma Co., Ltd Inhibrx ADRx* Johnson & Johnson Innovation, Beloteca Edico Genome INNOCART Advanced BioMatrix JLABS BioAtla eFFECTOR Therapeutics InnoPep Advanced Targeting Systems Jones Day BioCeryx Elcelyx Therapeutics Innovative Cell Technologies Advanced Tissue Scientific Kilroy Realty BioLegend Elixsys Innoviva Aerie Pharmaceuticals Biomatrica Emerald Cloud Lab Innovus Pharmaceuticals KPBS Agena Bioscience Biomyx Emerald Health Bioceuticals* Inovio Pharmaceuticals KPMG Agensys* BioNano Genomics Emerald Health Pharmaceuticals* InSilixia Latham & Watkins Aimmune Therapeutics Bioniz Therapeutics eMolecules Integrated DNA Technologies Marsh & McLennan Agency Aim RX Bionova Scientific* EndoCyclic Therapeutics Intercept Pharmaceuticals Mentus Aivocode* Bird Rock Bio EnduRx Pharmaceuticals International Stem Cell Merck Research Laboratories Aldevron BioSpyder Technologies Epeius Biotechnologies Intrexon Corporation Alector Mesa Biotech Biotheryx Esper Therapeutics Intrinsic LifeSciences Alkermes* Mintz, Levin, Cohn, Ferris, Glovsky BioWa Eton Bioscience Invetech Allakos and Popeo BlackThorn Therapeutics Evofem Biosciences Invitae Corporation* Alpine Roads Nixon Peabody Blade Therapeutics EvoRx Technologies InvivoGen AM Chemicals Novo Nordisk Boehringer-Ingelheim Expression Systems* Ionis Pharmaceuticals Ambryx Biotechnology NuVasive Bolt Therapeutics* EZ Labs Iovance Amgen Office Depot BP Biosciences Center* F1 Genomics* IRBCo. Ampersand BioPharma* Bristol-Myers Squibb F1 Oncology Isommune Panasonic Healthcare AmpliPhi Biosciences CalciMedica Fabrus Jecure Therapeutics Corporation* Amplyx Pharmaceuticals Caribou Biosciences Fate Therapeutics Karma Biotechnologies Patheon Amprion* Casebia Therapeutics FibroGen Kindred Biosciences Perkins Coie* Amyris Catalaize Fluoresprobe Sciences Koniku Pfizer Amgiocrine Bioscience Cayuga Biotech Forge Therapeutics Kureha Corporation* Animantis Prometheus Laboratories CeleCor Therapeutics* Forty Seven* Kura Oncology AnaptysBio PwC Cellese* Fress Therapeutics* Kyowa Hakko Kirin California Animal Cell Therapies Thermo Fisher Scientific Cell Care Therapeutics Galena Biopharma Lab Launch Annam Biosciences* TroyGould PC* Cellics Therapeutics Geltor La Jolla Biologics Ansun Biopharma Unisource Solutions Cello Therapeutics* Genalyte, Inc. La Jolla Pharmaceutical Company Antiva Biosciences

* New Members from May 2017 to October 2017

42 Biocom LifeLines Fall 2017 BIOCOM MEMBERSHIP

Ligand Pharmaceuticals Novoron Bioscience PrimeGen Biotech Seragon Pharmaceuticals Trianni Leading Biosciences Novvi Primity Bio Seventh Wave* Triphase Accelerator Lexent Bio Nucelis Primordial Genetics Single Cell Technology* Triton Algae Innovations Lin Bioscience Nucleus Biologics* Principia Biopharma Singlera Genomics Truvian Sciences, Inc. Linkage Bioscience Nuredis Procure Life Sciences* Singular Bio Twist Bioscience Corporation Lumena Pharmaceuticals Nurix Prognosys Biosciences SillaJen Biotherapeutics UCB MabVax Therapeutics OBI Pharma USA Protelica* Solstice Biologics Ultima Genomics MAPP Pharmaceuticals Obsidio Therapeutics Provivi Sophiris Bio US Specialty Labs Maverick Therapeutics Ocera Therapeutics PvP Biologics Sorrento Therapeutics Valtari Bio MAX BioPharma OcuNexus Therapeutics QED Bioscience SOVA Pharmaceuticals Vantari Genetics MedGenome Ohr Pharmaceutical QLSF Biotherapeutics Stason Pharmaceuticals* Vaxiion Therapeutics MatriSys Bioscience Omniox Quay Pharmaceuticals Limited StemImmune Velox Biosystems Maverick Therapeutic Oncternal Therapeutics Reflexion Pharmaceuticals* StemoniX Ventura Bio Center Meditope Bioscience Optimum Therapeutics Regude Biotechnologies Sunesis Pharmaceuticals Verdezyne MEI Pharma Orca Biosystems* Regulus Therapeutics Sun Genomics Verily Life Sciences Meiji Seika Pharma Orexigen Therapeutics REKA Health Sunovion Pharmaceuticals Verogen* Memphis Meats Origami Therapeutics REMD Biotherapeutics* Surrozen* Verndari Menarini Silicon Biosystems OrPro Therapeutics Rempex Pharmaceuticals Switch Bio* Vertex Pharmaceuticals Mercaptor Discoveries Otonomy Renew BioIndustries Sydnexis* Vet-Stem Metacrine Oxford Bio Therapeutics Renova Therapeutics Synova Life Sciences* ViaCyte MindWerks Bio Pacira Pharmaceuticals Repertoire Genesis Synthetic Genomics Vical Miraculex Pact Pharma Reset Therapeutics* Takeda Pharmaceuticals U.S.A. Vigil Dx* Mirati Therapeutics Parallume* Retrophin Tanabe Research Laboratories Viking Therapeutics Molecular Assemblies Patara Pharma Retro Virox Tarere Therapeutics Viracta Therapeutics Molecular Response Pathway Genomics REVOLUTION Medicines Target Discovery Vital Therapies Molecular Stethoscope Peptide Logic* Riboscience TCRCure Biopharma* Vineti Monsanto Perfect Day* Ridgeline Engineering T-Cure Bioscience* Vir Biotechnology* Multimeric Biotherapeutics Persephone Biome* RIFT Biotherapeutics TEGA Therapeutics Viscient Bioscience* Myokardia PersImmune Ritter Pharmaceuticals Tempo Therapeutics Vividion Therapeutics Myovant Sciences Pfenex Rohto Pharmaceutical Tenova Pharmaceuticals Wamberg Genomic Advisors* Nagano Science USA PharmAkea RxSight Theravance Wellspring Biosciences NantWorks Phenvogen Sapphire Energy Thesan Pharmaceuticals Wildcat Discovery Technologies NeuCyte Phoenix Molecular Designs* Samumed Tizona Therapeutics World Fusion Co., Ltd* Neurocrine Biosciences Pimera Samsara Sciences TL Biolabs Xcell Biosciences NeuroGenetic Pharmaceuticals Pipeline Therapeutics* Sanguine Biosciences Tocagen Xcell Unity* Neurona Therapeutics* Plex Pharmaceuticals Sanofi Tonbo Biosciences Xencor NF Techno Commerce Pliant Therapeutics Scripps Laboratories Tosoh Corporation* Yokogawa Electric Nirmidas Biotech Polynoma Second Genome TP Therapeutics Zavante Therapeutics Nitto BioPharma Polypeptide Laboratories Senomyx Trace-Ability, Inc. Zosano Pharma Nitto Denko Technical Poseida Therapeutics Senté Tracon Pharmaceuticals Notogen, Inc. Precision Nanosystems US* Sentynl Therapeutic Tragara Pharmaceuticals Novartis Pharmaceuticals PrimaPharma* SeqOnce Biosciences Trefoil Therapeutics

CRO/CMO

3DT Holdings Annova Chem Champions Oncology eStudySite inVentiv Health Clinical Abbiotec Aptuit Charles River Laboratories Explora BioLabs Invicro* ABL Argonaut Manufacturing Services ChemDiv Genea Biocells IriSys Absorption Systems Atheln ChemPartner Global Blood Therapeutics JRF Global* Abzena* Bavarian Nordic Cleave Biosciences Grand River Aseptic Manufacturing KaloBios Pharmaceuticals Accelagen Behavioral Pharma Clover Biomedical Systems* Hamamatsu Pharma Research Lab Launch Accenture Accelerated RD BioAuxilium Research CMIC Holdings Co* Hamari Chemical San Diego Research LakePharma* Acepix Biosciences* BioBlocks CNBE* Center Linear Clinical Research* Advinus Therapeutics* Bioclinova Covance* HD Biosciences Linical USA Agility Clinical Bio-Edge Crown Bioscience San Diego HTD Biosystems* Lovelace Biomedical Alkahest Bioserv Corporation* Cytelligen HTL Biotechnology* Lucidant Polymers Alphora Research Cassia Davos Chemical ImmunoActiva Mediconomics Alliance Protein Laboratories Catalaize DDSTUDIO* Infinite Chemical Analysis Labs* MedSource A&M Biomedical Catalent Diagnomics IMS Health MEIRxRS American Peptide Company Cato Research Drug Delivery Experts InClinica, Inc. MicroConstants AnaBios Cellecta Enplas Americas* Integrium Clinical Research MPI Research

Biocom LifeLines Fall 2017 43 BIOCOM MEMBERSHIP

My Chem LLC South Bay Biomics BillionToOne Fallbrook Engineering Omniome Nanosyn SRD Co., LTD* Biocept Fresca Medical OncoSec Medical Neox USA STA Pharmaceuticals BioDx GenomeDx Biosciences Organovo Neuropore Therapies Starfish Medical BioFluidica GenWay Biotech Patient Safe Solutions Neuroservice Stem Express Biological Dynamics GIMDx Precision Diagnostics Neuro-Sys SureClinical Biomerica Glaukos Corporation Profusa Norac Additives SynteractHCR Biospacific Glysens Prometheus Laboratories Norac Pharma* TCR Medical Corporation bioTheranostics Harbor Med Tech Pulse Biosciences Novasyte* Therapeutics Bio Trace Medical Heart Metabolics USA Q-Bridge Solar Oncolytics Biotech Tioga Research BlueNovo Biosystems, Inc. Hitachi Chemical Research Center Qico PharPoint Research Toxikon Breathe Technologies Ichor Medical Systems QT Medical PharmaDirections Toyota Tsusho Corporation Bruin Biometrics Ignyta Quidel PharmaLegacy Triligent International Burl Concepts Imagion Biosystems Quinn Medical Pharmapace Uquifa, Inc. Canary Health ImpediMed Rebound Therapeutics Pharmaron Vala Sciences Cell Idx ImpriMed* ReCor Medical Pharma Test Services Ventura Bio Center CeloNova BioSciences ImThera Medical Renew Medical ProSciento VIRAPUR Ceterix Inari Medical ReShape Medical Provivi Vista Biologics Corporation* Chapter Diagnostics* Inceptus Medical REVA Medical PSI CRO Wax-It Histology Services ChromaCode INOVA Diagnostics ReVision Optics Puracyp Zensun USA Click Diagnostics Interpreta Simplify Medical Qoolabs Zyagen Cliniqa Corporation Interventional Spine Sirigen QPS CombiMatrix Invivoscribe Technologies Solekai Systems Quadrants Scientific Compellon Ionian Technologies Sonendo Quay Pharmaceuticals Limited MEDICAL DEVICE Confirm Biosciences KFx Medical Specific Technologies R2M Pharma* CTK Biotech Kurin SpectraScience Rapid Novor & DIAGNOSTIC CVAC Systems Luminex Corporation Spinal Elements Recro Gainesville* Cytori Therapeutics Lumira Suneva Medical ReoLab Acon Laboratories DermTech International MARDX Diagnostics Sysmex America Reveal Biosciences Adagio Medical DexCom Mass Spec Lab Tandem Diabetes Rho Aethlon Medical Diadexus MERU VASImmune* Terumo Cardiovascular Systems Robarts Clinical Trials Alpha-Tec Systems Dorsa Vi USA Micell Technologies Corporation RxGen AltheaDx Drawbridge Health* Millennium Health Tokai Medical Products SD Chem Aptitude Medical Systems DNA Electronics Minerva Surgical Transcend Medical Shang Pharma Innovation* Astute Medical Elixir Medical Corporation Nano Imaging Services Tristan Technologies SeqOnce Biosciences AVACEN Medical Emerge Diagnostics Nanomedical Diagnostics Trovagene SG Scientific Awesome Medical Company Endologix NeuroStructures* Xtant Medical Shamir Insight, Inc. Axonics Modulation Technologies Entra Health Neurvana Medical Sherpa Clinical Packaging Banyan Biomarkers Epic Sciences NucleusHealth Solana Biosciences* Berkley Lights Epitope Diagnostics NuFACE

CSU, CSUPERB Program Los Angeles Biomedical Research San Diego Employers Association UC San Diego Extension NON-PROFIT Drugs & Diagnostics Tropical Diseases Institute San Diego Regional Chamber of UC San Diego Office of Innovation & East Bay Economic Development Los Angeles EDC Commerce Commercialization American Cancer Society, Border GlycoAnalytics, UC San Diego Lowy Medical Research Institute San Diego Regional Economic UCI’s Office of Research Sierra Region Hayward Chamber of Commerce MiraCosta College Biotech Program Development Corp. UCLA Technology Development Group Biomedical Manufacturing Network Human BioMolecular Research Molecular Medicine Research San Diego Supercomputer Center UCSD, Department of Bioengineering Calibr Institute Institute (UCSD) UCSD, Office of Advancement California NanoSystems Institute Huntington Medical Research Center Mt. San Jacinto College San Diego Workforce Partnership UK Department for International (CNSI)* IDA Ireland Pasadena Bio Collaborative Sanford Burnham Prebys Medical Trade California State University, Institute of Engineering in Medicine Incubator* Discovery Institute University of San Diego San Marcos Institute of Quantitative Systems PhRMA Scottish Development International USC Stevens Center for Innovation Cal State University, Los Angeles Pharmacology (IQSP) Point Loma Nazarene University Scripps Health Western University of Health Services Chan Zuckerberg Biohub J. Craig Venter Institute PRISM Scripps Institution of Oceanography Zhuhai Commercial Service, North Cedars-Sinai Medical Center Office of Kaiser Permanente Rady School of Management, UCSD Scripps Research Institute America Tech Transfer Keck Graduate Institute* Salk Institute for Biological Studies SDSU, Graduate & Research Affairs Children’s Hospital LA* La Jolla Bioengineering Institute San Diego Biomedical Research Society for Brain Mapping & CIRM La Jolla Institute for Allergy & Institute Therapeutics City of Berkeley Office of Economic Development* Immunology San Diego Blood Bank SRI International City Of Murietta Lawrence Family Jewish Community San Diego Clinical and Translational Torrey Pines Institute for Molecular CONNECT Center Research Institute, UCSD Studies Consulate of Canada Life Science Innovation Network San Diego Community College District UCLA School of Medicine Japan San Diego County Water Authority UC San Diego Health * New Members from May 2017 to October 2017

44 Biocom LifeLines Fall 2017 BIOCOM MEMBERSHIP INDIVIDUAL

Antoinette Azevedo Bionest Partners Fluidigm Corporation Medline Industries Sofinnova Ventures Carol Gallagher BioSurplus Forward Ventures Medscape Education (Web MD) Square 1 Bank Dan Burgess BioTix Fragomen, Del Rey, Bernsen & Loewy MIB Worldwide Chauffeured Services Stradling Yocca Carlson & Rauth Decky Goodrich Blue Sky Broadcast Full Spectrum Analytics MI-Box Moving & Mobile Storage of SD TCI America Donna Janson Blue Sky Marketing Group* Genstar Technologies Morrison & Foerster Technical Safety Services Elliot Parks Bridgewest Capital Management Global Source Ventures Navigator Business Solutions Telepacific Communications James Eppink BSM USA* GMI Building Services Objective Capital Partners The Newport Group John Kavanagh Buchanan Ingersoll & Rooney Golden EHS Consulting Occupational Services The University of Tokyo Edge Capital Co. Peter Preuss Burger Construction* Grande Colonial Office Troops Transnetyx Richard Ledford Caliber Associates Ground Zero Pharmaceuticals Oxford Finance Trials.ai Stan Kim California Manufacturing Technology Gunderson Dettmer Pall ForteBio TriNet Consulting Halbert Construction Praxis Life Sciences TUV SUD America Cambridge Research Biochemicals Halloran Consulting Group PR Newswire Unanet Cardinal Health Regulatory Sciences HCP Life Science Estates Prevost Construction Unifirst KEY PROVIDER CBRE Heritage Global Partners* Procopio, Cory, Hargreaves & Savitch UPS Chubb Group of Insurance Companies H.G. Fenton Company Project Management Advisors Vault Bioventures Covington & Burling City Wide Maintenance* Hyatt Regency La Jolla at Aventine Providential Real Estate VDP Direct Cushman & Wakefield CohnReznick LLP IMEC Prudential Cleanroom Services Veolia Innovative Advancement* Controlled Contamination Services J.T. MacMillan Photography Qiagen* Watson Biolab USA Qualcomm Corning Jones Lang LaSalle Retirement DNA Weka.IO San Diego Gas & Electric CryoPort Kaneca Corporation Robert Half Zayo Group CSM Kilroy Realty RxC International* Zef Scientific Cymer Knobbe, Martens, Olson & Bear Sartorius Dassault Systems Biovia Corp Layer3 Security Services Savills Studley PROVIDER Delawie Leadership Edge ScaleMatrix Dentons LemonTree Partners* SecureDocs 2Connect Dowling & Yahnke Leverage Concierge Seismic Software C3 Risk & Insurance Services DPR Construction Life Science IT Sequoia Consulting Group 4G Clinical Echo Laboratories Lonza AG Sharp Business Systems AER Travel Elsevier Managed Laboratory Services Sheppard Mullin Richter & Hampton AMN Healthcare Essen Bioscience Marken Shred-it Arivis* Ferguson Pape Baldwin Architects Mark Hurtt Consulting Siemens Industry* AVI Systems* Fisher & Phillips Mayer Hoffman McCann Silicon Valley Bank Azzur Group Fjord Ventures McDermott, Will & Emery Slone Partners Bench International* * New Members from May 2017 to October 2017 UNITE Accelerating Life Science Across California

Biocom LifeLines Fall 2017 45 10996 Torreyana Rd, Suite 200 San Diego, CA 92121-3021

www.Biocom.org 858.455.0300 Please send a change of address or subscription request to [email protected].

Gain the essential Gain the essential kGnaoinw ltehdeg ees sneenetdiaedl to knowledge needed to kdnevoewlolepd gmee ndeiceadle dde tvoic es develop medical devices fdreovmel ocpo nmceepdtic taol devices from concept to cfroommm ceorncciaelpizt atoti on. commercialization. commercialization. Regulatory Affairs Regulatory Affairs fRoerg Muleadtoicrayl ADfefavicrse s for Medical Devices Sfpoerci aMlizeedd Ciecrtaificla Dte evices Specialized Certificate Specialized Certificate

extension.ucsd.edu/RAMedDevices extension.ucsd.edu/RAMedDevices extension.ucsd.edu/RAMedDevices

Gain the essential Gain the essential knowledge needed to knowledge needed to develop medical devices develop medical devices from concept to from concept to commercialization. commercialization. Regulatory Affairs Regulatory Affairs for Medical Devices for Medical Devices Specialized Certificate Specialized Certificate

extension.ucsd.edu/RAMedDevices extension.ucsd.edu/RAMedDevices